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Summary of the thesis 
Objectives: To investigate how cardiac function, remodeling and gene expression are 
affected in pregnancy in response to cardiovascular stress and to detect possible adverse 
effects of chronic AngII infusion, transverse aortic constriction (TAC) or high-intensity 
interval training (HIIT) on the fetus.  Additionally we wanted to evaluate if coronary 
endothelial function is influenced by pregnancy and increased cardiac afterload. 
Materials and methods: Pregnant and non-pregnant rats were subjected to chronic AngII-
infusion, TAC or HIIT in three separate studies. Echocardiography was used to evaluate 
maternal heart function and fetal hemodynamics. Blood flow velocities in the left main 
coronary artery were measured using Doppler echocardiography, and coronary flow reserve 
(CFR) was assessed using 3.5% inhaled isoflurane as a vasodilating agent. A conductance 
catheter placed via the right carotid artery was used for invasive measurements of aortic blood 
pressure and left ventricle (LV) pressure-and volume. Histological sections of the maternal 
LV were used to determine collagen content (Sirius Red staining), vessel density (β-actin 
immunolabelling) and myocyte size (Toluidine Blue). RT-PCR was used to quantify the gene 
expression in maternal myocardium, placenta, fetal heart and fetal liver. Total antioxidant 
capacity and oxidative stress (peroxidase and superoxide dismutase activity and 
malondialdehyde content) was measured in the placentas, fetal hearts and livers in the HIIT-
study.  
Results: Chronic AngII infusion resulted in an increase in myocardial collagen content, and 
pregnancy reduced this effect. Vessel density in LV was decreased in AngII infused compared 
to sham non-pregnant rats, but not significantly in pregnant rats. Fetal hemodynamics was not 
affected by chronic AngII-infusion. Calculated stroke work in pregnant TAC rats was double 
compared to pregnant shams, whereas it was only 35% higher (not significant) in non-
pregnant TAC rats compared to non-pregnant shams. The ratio of β-MHC to α-MHC 
expression was higher in pregnant TAC compared to non-pregnant TAC. Myocyte transverse 
circumference was increased by pregnancy, but not by TAC. HIIT did not alter maternal 
cardiac structure or function, fetal growth or oxidative stress and total antioxidant capacity in 
the placenta, fetal heart and fetal liver. However, the expression of some genes related to 
oxidative stress or cardiac remodeling was changed in fetal heart and liver. CFR could be 
calculated in 60 of 75 (80%) rats. There were no differences in CFR between rats with 
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increased afterload (AngII or TAC) and sham controls. CFR was lower in pregnant sham 
compared to non-pregnant sham rats.  
Main conclusions: AngII infusion caused cardiac hypertrophy in pregnant rats. However, 
pregnancy was protective against fibrosis and preserved angiogenesis in AngII infused rats. 
On the other hand, the differences in cardiac structure, function and gene expression between 
pregnant and non-pregnant rats following TAC indicated that increased afterload may be less 
tolerated in pregnancy. Pregnancy does not lead to significant heart hypertrophy in rats, but 
induces changes in the expression of a wide range of genes involved in cardiac remodeling 
independent of afterload. HIIT is feasible and well tolerated by pregnant rats. CFR is reduced 
in late pregnancy, but not influenced by increased afterload caused by TAC or chronic AngII 
infusion. HIIT does not induce significant changes in oxidative stress in the fetus, but altered 







1.1 Cardiovascular adaptations to pregnancy 
This thesis will focus on how pregnancy influences heart function, structure and gene 
expression in health and disease.  Women who become pregnant undergo profound alterations 
of the cardiovascular system. In this section the pregnancy induced adaptive changes of the 
heart and cardiovascular system are summarized. 
1.1.1 Heart rate and cardiac output  
The first hemodynamic adaptation to take place is an increase in resting heart rate which starts 
between 2 and 5 weeks gestation and continues throughout pregnancy [1, 2]. Maternal heart 
rate is also increased during exercise, but less evident at higher intensities. The increase in 
heart rate is primarily a result of reduced parasympathetic modulation [3]. LV stroke volume 
starts to increase early in pregnancy, reaching a plateau at approximately 24 weeks of 
gestation [2]. Thus the rise in total cardiac output, the product of stroke volume and hear rate, 
is most pronounced in the first trimester with more than 50% of the change in cardiac output 
taking place before 8 weeks gestation [4]. In the third trimester, the gravid uterus may 
obstruct the inferior vena cava when lying in the supine position, leading to reduced venous 
return to the heart and a subsequent decrease in cardiac output. 
1.1.2 Myocardial contractility 
Data on how pregnancy will influence myocardial function is conflicting. Some researchers 
have reported an increase in LV contractility during pregnancy [5-7], while others have found 
no change [8] or decrease in contractile function of the maternal heart in health pregnancies 
[9]. In vivo measurements of cardiac function in pregnancy are highly dependent on the 
loading conditions of the heart and these are influenced by a variety of factors in pregnancy 
[10, 11]. 
1.1.3 Systemic vascular resistance and blood pressure 
During early pregnancy active vasodilatation through the action of local mediators as nitric 
oxide and prostacyclin as well as increased blood flow in the uteroplacental circulation leads 
to a decrease in systemic vascular resistance [5, 8, 9, 11-13]. Systemic BP falls early in 
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gestation and diastolic BP will average 10 mmHg bellow non-pregnant values in the second 
trimester before gradually increasing towards basal values at term [11, 13].  
1.1.4 Blood volume 
In normal pregnancies blood volume will start to increase between 10 and 20 weeks of 
pregnancy averaging a total blood volume 40-45% above non-pregnant levels [14-18]. Two 
thirds of the rise consists of increased plasma volume where as the rest is attributed to an 
increase in red blood cell volume, leading to a relative hemodilution and lower levels of 
hemoglobin. Similarly, colloid osmotic pressure decreases during pregnancy, lowest at 30-34 
weeks of gestation [19]. The increase in plasma volume is likely to be triggered by the fall in 
systemic vascular tone in pregnancy [12].  
1.1.5 Aerobic capacity 
Resting or su ma imal    2 during weight-bearing exercise increases proportional to 
maternal weight gain during pregnancy whereas    2max during pregnancy is poorly explored 
due to the perceived risk of inducing fetal stress during testing including reports of fetal 
bradycardia [3, 20]. However there is evidence that    2max is conserved during pregnancy, 
and athletes and physically fit women may even increase their    2max following pregnancy 
indicating that pregnancy may have an added effect in well trained women [17, 21]. 
1.1.6 Adaptation of the endocrine system 
Pregnancy influences a wide range of hormones. Progesterone is produced by the corpus 
luteum in the luteal phase of the menstrual cycle and early pregnancy. After eight weeks of 
pregnancy, placental trophoblasts become the main source of progesterone. Progesterone and 
estrogens increases during pregnancy, and both sex steroid hormones can influence cardiac 
growth, cardiac output and blood volume in animals. Progesterone can induce hypertrophy 
whereas estradiol have anti-hypertrophic properties and increases cardiac output [22]. Relaxin 
produced by the corpus luteum contribute to the decrease in vascular resistance and increased 
cardiac output in pregnancy [23]. How the levels of circulating catecholamines are affected by 
pregnancy is debated [22], but noradrenalin infusion leads to less vasoconstriction in healthy 
pregnant women, compared to both non-pregnant women and women with pregnancy-induced 
hypertension [24]. In pregnant women an increase in estrogens leads to  an upregulation the 
renin-angiotensin system (RAS)  and the serum AngII levels are increased [25]. However, in 
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healthy pregnancies RAS activity remains low as AngII sensitivity is decreased [26], due to 
specific changes in the AngII-receptors sensitivity [25, 27, 28]. 
1.2 Differences between physiological and pathological heart 
hypertrophy 
 
Figure 1 Physiological heart hypertrophy 
Schematic representation of the left ventricle in short axis showing physiological postnatal 
heart growth. In the human heart endurance training or pregnancy leads to heart hypertrophy 
characterized by a proportional increase in wall thickness and chamber enlargement. The 
hypertrophy is reversible, i.e. the heart will go back to normal size postpartum or if the 
training ceases. Figure modified from Bernardo et al [29] . 
Increased ventricular mass as a response to chronically increased afterload or volume 
overload on the heart is referred to as pathological hypertrophy.  Cardiac hypertrophy is 
considered a poor prognostic sign and may represent the first stage in development of heart 
failure. However, the heart hypertrophy observed in postnatal growth [30], in response to 
exercise training [29, 31, 32] and in pregnancy [7, 22, 33, 34] differs from pathological 
hypertrophy both at the structural, functional and molecular levels and may be referred to as 
physiological hypertrophy [29, 31, 35] (Figure 1). The growth of human hearts is most rapid 
during the first postnatal months. The neonatal period is characterized by myocyte hyperplasia 
whereas in the heart growth of childhood the total number of myocytes remains relatively 
constant while myocyte volumes and deposition of collagen and the number of connective 
tissue cells increases [30].  
Different stimuli induce different forms of ventricular hypertrophy. A pathologically 
increased afterload, such as in hypertension or in obstruction of the outflow tracts of the 
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ventricles, increases systolic wall stress and typically lead to a concentric hypertrophy with 
thickening of the walls of the heart, a small ventricular chamber and increased myocyte 
diameter whereas a pathologically increased volume load, as can be seen in valve disease, 
such as in aortic regurgitation, produces increased diastolic wall stress and may lead to an 
eccentric hypertrophy with an increased luminal diameter, a thinner ventricular wall and 
increased myocyte length [22, 29, 35] (Table 1 and Figure 2). 
Table 1 Characteristics of physiological and pathological heart hypertrophy 
 Physiological Concentric Eccentric/dilated 
LV wall and 
chamber growth 
LV wall = 
LV chamber 
LV wall > 
LV chamber 
LV wall << LV 
chamber 
Myocyte growth Proportional Length < Width Length >> Width 
Cardiac dysfunction No Maybe Advanced 
Fibrosis No Yes Extensive 
Myocyte damage No Necrosis and 
apoptosis 
Myocyte cell death 
Table based on Bernardo et al [29], Chung et al [22] and Heineke et al [35]. 
Physiological stimuli may also induce concentric and eccentric hypertrophy. Both endurance 
training and pregnancy will increase venous return to the heart leading to increased volume 
load and an hypertrophy characterized by a proportional increase in wall thickness and 
chamber enlargement, in contrast to the thinning of the ventricular walls seen in pathological 
eccentric hypertrophy following volume overload or the concentric hypertrophy following 
pressure overload [29]. 
Despite some similarities at the macroscopic level, there are distinct differences between 
physiological and pathological heart hypertrophy at the structural, functional, metabolic and 
molecular level (Table 1). Pathological hypertrophy causes cell death via apoptosis and 
necrosis leaving room for extracellular accumulation of collagen causing fibrosis. The 
increased stiffness of the ventricles and impaired electrical signal conduction lead to impaired 
mechanical function of the ventricles. Reduced capillary density and interstitial accumulation 
of fibrotic tissue lead to reduced tissue oxygen tension, myocardial ischemia, and further cell 
death. These sequences of structural and functional changes may eventually lead to advanced 
cardiac dysfunction and heart failure [29, 35]. The heart is capable of utilizing fatty acids, 
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glucose and lactate as substrates for ATP-production, with fatty acid oxidation responsible for 
2/3rds of the ATP synthesis in the normal heart [36]. In pressure induced heart hypertrophy 
there is an early impairment of fatty acid oxidation followed by a progressive decrease in 
glucose oxidation and overall ATP-production before development of heart failure [37]. Thus 
the failing heart could be referred to as an engine out of fuel [38].  In heart hypertrophy 
following high intensity aerobic exercise, there is improved mitochondrial function and an 
increase in glucose oxidation allowing more effective energy production as glucose oxidation 




Figure 2 Pathological heart hypertrophy 
Schematic representation of the left ventricle in short axis. Volume overload, as seen in valve 
regurgitation, leading to eccentric hypertrophy. Pressure overload, as in systemic 
hypertension or obstruction of LV outflow tract, leads to concentric hypertrophy. Heart 
dilatation and failure represent the end stage of these processes. A sick or damaged 
myocardium, as seen in dilated cardiomyopathy or after massive myocardial infarction, may 
lead to dilated heart failure without hypertrophy. Figure adapted from Heineke et al [35] and 
Bernardo et al [29] . 
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Table 2 Differences between physiological (caused by pregnancy and exercise) and 
pathological cardiac hypertrophy 
 Pregnancy Exercise Pathological 
Cardiac function - -/↑ ↓↓ 
Reversibility + + - 
Fetal gene induction - - ↑ 
Fibrosis - - ↑ 
Angiogenesis - -/↑ ↓ 








Table adapted from Chung et al [22]. 
Physiological heart hypertrophy following endurance training and in pregnancy are often 
regarded as similar phenomena following different stimuli. However, Chang et al have 
pointed out several characteristics that distinguish heart hypertrophy in pregnancy from 
hypertrophy following exercise training [22] (Table 2), and describe evidence of specific 
cardiac transcriptional profiles defining pregnancy and exercise [40]. 
1.3 Increased afterload on the heart in pregnancy 
The cardiovascular and hemodynamic changes that take place in pregnancy has a potential to 
make the heart more vulnerable to stress, and manifestations of heart conditions well 
compensated for before conception can unmask during pregnancy. The pregnant woman may 
be at risk for complication during pregnancy, delivery and in the postpartum period [11]. 
1.3.1 Pregnancy in women with congenital heart disease 
Advances in cardiac surgery and improved care for children with congenital heart defects has 
lead to an improved survival, and there is a growing population of women of childbearing age 
with congenital heart disease [11, 41, 42].  Many of these will have residual impairment of 
their heart function that increases their risk of cardiovascular complications during pregnancy 
[11, 43, 44]. Significant LV outflow tract obstruction, as can be seen in aortic stenosis, 
coarctation of the aorta, interrupted aortic arch and in some complex cardiac defects, will 
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increase afterload on the ventricles. Severe symptomatic LV outflow tract obstruction is a 
contraindication for pregnancy and should be treated before pregnancy, or the woman should 
be counseled against pregnancy [11]. However, some women with significantly increased 
afterload on the heart will get pregnant, and knowledge of how pregnancy influences cardiac 
structure and function is crucial for providing optimal care for these women and their fetuses. 
1.3.2 Hypertensive disorders of pregnancy 
Systemic hypertension is often the cause of increased cardiac afterload in pregnancy.  
Hypertension may be preexisting, as in essential hypertension or as a part of metabolic 
syndrome, or it can be secondary to other medical conditions, such as renal disease or 
endocrine disorders. Failure of the cardiovascular system to adapt to physiological changes of 
pregnancy can lead to hypertensive disorders of pregnancy, frequently associated with 
adverse outcomes for mother and offspring [11, 45]. Approximately 3-10 % of pregnancies 
are complicated by preeclampsia, characterized by hypertension developing together with 
proteinuria after 20 weeks of gestation. Although preeclampsia is a heterogenous condition 
and several mechanisms may be involved, abnormal placentation, with poor penetration of 
cytotrophoblasts into the maternal deciduas and adjacent spiral arteries, appears to be central 
in its pathophysiology [46]. Early onset disease is more severe and associated with a higher 
rate of premature birth, small for gestational age neonates as well as a higher rate of 
recurrence. As we are currently not able to effectively predict and prevent the development of 
preeclampsia, early recognition is required to assure adequate antenatal care and management. 
Premature delivery may be necessary to prevent eclampsia, the end stage of the disease 
characterized by generalized seizures, or to rescue fetuses with severely compromised 
circulation and growth restriction due to placental insufficiency.  
In contrast to healthy pregnancies, where decreased systemic vascular tone leads to an 
increase in circulating blood volume, relative hemodilution and decrease in colloid osmotic 
pressure, preeclampsia is characterized by high vascular resistance due to peripheral 
vasoconstriction and decreased arterial compliance [47]. Thus the increase in blood volume is 
small, or absent, leading to a relative hemoconcentration compared to in healthy pregnancies 
[16].  Endothelial dysfunction may play a central role in the pathogenesis of preeclampsia. 
There is firm evidence that several circulating factors that are released by the injured or 
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activated placental endothelium in preeclamptic women are capable of inducing endothelial 
dysfunction in the maternal circulation [47]. 
 
Figure 3 The renin-angiotensin system (RAS) in pregnancy. 
RAS components and AT1-receptors in healthy pregnancy (purple arrows) and preeclampsia 
(red arrows).  
The regulation of the RAS in preeclampsia differs from that in healthy pregnancy. AngII 
levels are high but the pressor response to AngII is reduced in normal pregnancy. 
Preeclamptic women have lower circulating levels of RAS components, but increased AT1-
receptor activation [25, 27, 28] (Figure 3). Renin synthesis is suppressed in preeclampsia, 
possibly due to negative-feedback as stimulation of the AT1-receptor suppress renin release 
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[25]. The discovery of AT1-receptor agonistic autoantibodies (AT1-AA) in preeclamptic 
women may explain this feature [48-52]. In rats AT1-AA reduces trophoblast invasion [51] 
and induces renal changes and atherosis-like lesions in the spiral arteries of the placenta 
similar to in what is seen in women with preeclampsia [52]. Furthermore, AT1-AA can 
activate the inflammatory response similar to what is seen in preeclampsia through 
stimulation of ROS production [27, 51, 53], and AT1-AA from preeclamptic women can 
induce preeclampsia-like changes if infused into pregnant mice [54].  
1.4 Endurance training and exercise in pregnancy 
Cardiovascular training, in terms of repeated episodes of physical activity performed over a 
longer period  causes adaptations in the cardiovascular system that enables the trained person 
to increase physical performance i.e. exercise at a higher intensity or at the same intensity for 
a longer period of time. Regular endurance training increases LV cavity volume, stroke 
volume and thus maximal CO leading to increased    2max reflecting an improved overall 
aerobic capacity and a higher level of cardiovascular fitness [17].  
1.4.1 Training in normal pregnancies 
Clinical guidelines encourage moderate exercise in pregnancy due to its multiple beneficial 
effects for both the mother and her offspring [17, 55-57]. In the long-term, women who 
continue to exercise during pregnancy appear to exercise at a higher intensity, deposit less fat, 
improve fitness, have a lower cardiovascular risk profile, a more favorable metabolic profile 
with less gestational diabetes, lower incidence of low back pain and urinary incontinence and 
reduced symptoms of depression compared to women who cease to exercise during pregnancy 
[17, 58, 59]. In a study by Clapp et al women who continue to engage in vigorous training 
during pregnancy had babies that weigh slightly less than among the regular training women 
who quit exercise in pregnancy. There were no negative effects on physical growth or 
neurodevelopmental outcome at five years, exercise offsprings performed slightly better on 
Wechsler scales and tests for oral language skills, and they weighed less and had less 
subcutaneous fat deposits [60]. Well-trained athletes tolerate high volumes of training during 
uncomplicated pregnancies and aerobic training during pregnancy may even have an additive 
effect on physical fitness post pregnancy compared to before pregnancy [21, 61]. However, 
there remains some concern regarding high intensity training because of the possible adverse 
effect on the placental blood flow and episodes of fetal bradycardia observed in pregnant elite 
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athletes training at high intensity above 90% of maximal heart rate examined in the second 
trimester [20]. Thus, a recent comparison of guidelines for physical activity during pregnancy 
identified conflicting recommendations in between countries regarding vigorous-intensity 
activity in pregnancy [57].  
1.4.2 Training in complicated pregnancies 
Although there is good evidence that training during healthy pregnancy is beneficial, there are 
concerns about how to advice women with complicated pregnancies. 
1.4.2.1 Preeclampsia 
A systematic review of evidence indicates a trend towards a protective effect of physical 
activity in the prevention of preeclampsia [62]. Exercise may protect against preeclampsia by 
reducing oxidative stress, improving placentation and preventing endothelial dysfunction. 
Training during pregnancy might mitigate the effects of placental insufficiency or the 
angiogenic imbalance associated with preeclampsia [62, 63]. However, a large (>85000 
pregnant women) prospective cohort study from Denmark indicated that physical activity for 
more than 270 minutes per week may increase risk of severe preeclampsia.  
1.4.2.2 Heart disease 
Evidence based recommendations of how to balance the possible risk related to strenuous 
exercise against the advantages of physical fitness in pregnancies complicated by heart 
disease are lacking.  In the European Society of Cardiology (ESC) Guidelines on the 
management of cardiovascular disease during pregnancy exercise testing is recommended to 
assess disease severity and predict outcome but do not advise for or against physical activity 
in pregnancy in different settings of heart disease in pregnant women [11].  
1.4.2.3 Adiposity and diabetes 
There is some evidence that physical training in pregnancy reduces risk of gestational diabetes 
and restricts weight gain in healthy pregnant women [56, 59, 64, 65]. However, the 
information available in the literature is limited with regard to the role of physical activity for 
pregnant women with established diabetes mellitus or severe obesity. According to the 
American College of Obstetricians and Gynecologist committee opinion for obesity in 
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pregnancy “...all overweight or obese women, ... should be encouraged to follow an exercise 
program.” However, what such an exercise program should entail is not specified [66]. 
1.5 Clinical evaluation of cardiovascular function in pregnancy 
As summarized earlier, pregnancy induces a variety of hemodynamic changes which may 
alter the balance in compensated cardiovascular diseases and put the pregnant woman or fetus 
at risk. All women in reproductive age with significant cardiovascular disease should be 
counseled before planning to get pregnant. In pregnant women with cardiovascular disease a 
throughout cardiovascular assessment is required to detect women at risk of adverse outcome 
and to customize an adequate cardiovascular follow-up throughout pregnancy, labor and in 
the postnatal period [11]. In addition, previously undiagnosed heart conditions may become 
symptomatic due to the hemodynamic alterations in pregnancy and pregnancy associated 
cardiovascular diseases like peripartum cardiomyopathy. More commonly, hypertensive 
disorders like preeclampsia will debut during pregnancy.  
In all pregnancies, a general history should be taken and a clinical examination including 
auscultation of the heart and measurement of blood pressure should be performed at regular 
intervals, and if heart disease is suspected further examinations should be done, and followed 
up accordingly [11].  
Procedures involving radiation exposure should be minimized, and if possible, deferred to 
after 12 weeks of gestation to reduce the risk of radiation induced congenital malformations. 
Computer tomography is not recommended. Magnetic resonance imaging may be used to 
diagnose complex heart defects or aorta disease, but gadolinium should be avoided in 
pregnancy.  
Electrocardiography (ECG) and echocardiography are non-invasive procedures that can be 
performed safely, and repeated if necessary, in pregnancy.  In late pregnancy the heart is 
rotated towards the left and there is a 15-20 left axis deviation on ECG.  Changes in ST 
segments, Q wave and T wave as the heart changes position can mimic LV hypertrophy. 
Echocardiography is indicated when dyspnoea occurs during pregnancy or a new pathological 
murmur is heard. In some cases, such as in women with complex congenital heart disease, 
transeosophagal echocardiography may be a useful tool [11].  
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Exercise testing is useful in assessing functional capacity in pregnant women with congenital 
heart disease or asymptomatic valve disease. According to ESC Guidelines submaximal 
exercise test to 80% of predicted maximal heart rate should be used in asymptomatic pregnant 
women with suspected cardiovascular disease [11]. Dobutamine stress test should be avoided. 
Stress echocardiography can be used to detect ischemia or prior to conception to assess 
myocardial reserve in patients with cardiomyopathy, valvular disease or congenital heart 
defects and reduced LV function.   
Impedance cardiography (ICG) is a highly accessible, non-invasive, operator-independent and 
easy to perform non-invasive test to measure CO in pregnancy, and the new generation of 
ICG machines have been validated and shown to be accurate, reproducible, reliable and useful 
also in pregnant population [67, 68] 
Endothelium-dependent vasodilatation can be examined non-invasively in humans measuring 
flow mediated dilatation (FMD) of the brachial artery [69, 70], and several studies have 
evaluated FMD in pregnancy [71-77]. However, it is debated whether endothelial function in 
the peripheral vessels correlates with endothelial function in the coronary vascular bed [70, 
78-80]. We are not aware of any published studies evaluating endothelial function in the 
coronary circulation during pregnancy, and to our knowledge the effect of increased afterload 
on coronary flow reserve (CFR) during pregnancy has not been reported.  
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2. Aims of the thesis 
The aims of this thesis were to investigate how cardiac function, remodeling and gene 
expression are affected in pregnancy in response to cardiovascular stress and to detect 
possible adverse effects of chronic AngII infusion, TAC or HIIT on the fetus.  Additionally 
we wanted to evaluate if coronary endothelial function is influenced by pregnancy and 
increased cardiac afterload. 
The specific objectives were to: 
 Investigate the effects of chronic AngII infusion on the hearts of pregnant rats and to 
test the hypothesis that pregnancy protects against presumed detrimental changes 
caused by AngII.  
 Investigate the effect of isolated chronic pressure load induced by TAC on the hearts 
of pregnant rats and to test the hypothesis that pregnancy is protective against the 
negative effects of increased afterload on the heart.   
 Evaluate whether an established model of HIIT in rats is applicable in pregnancy and 
to investigate the effect of HIIT on the maternal heart. 
 Determine if HIIT has any adverse effects on the fetus. 
 Evaluate a non-invasive method of assessing CFR in rats using high concentration of 
inhaled isoflurane for coronary vasodilation. 
 Investigate the differences in CFR between pregnant and non-pregnant rats and study 




3. Methods and methodological considerations 
We used animal experiments to approach clinical problems related to cardiac remodeling in 
pregnancy. Ideally experiments should have been performed on humans. However, to test the 
effects of increased afterload on the heart, we had to do invasive procedures that could not be 
performed in pregnant women for obvious ethical reasons. Despite species differences, animal 
studies have some advantage compared to studies in human as they can be performed under 
strictly controlled laboratory conditions. Using animals of the same strain, age and size results 
in considerably less individual variability, and thus a lower number of subjects are necessary 
to find relevant differences between groups.  
Rats are often used as animal models in pregnancy research because they have a similar type 
of placenta to human [81] and the duration of rat pregnancy is relatively short (~21-22 days). 
Furthermore, rats are regarded as robust when it comes to tolerating surgical interventions and 
there is an abundance of experiments performed investigating circulatory physiology in non-
pregnant rats. Compared to mice, larger size of rats makes it is easier to investigate their heart 
function using echocardiography and intracardiac conductance catheter.  
3.1 Animal models 
All animal experiments were performed at Unit of Comparative Medicine, Faculty of Health 
Sciences, University of Tromsø and experiments conformed to the Directive 2010/63/EU of 
the European Parliament on the protection of animals used for scientific purposes [82]. All 
procedures were approved by the Norwegian Committee on Ethics in Animal 
Experimentation with project ID 907 (Paper A and D), ID 2177 (Paper B and D) and ID 2853 
(Paper C). In Paper A, B and D Wistar rats where used. In Paper C Sprague-Dawley rats were 
used based on experience from previous studies on a HIIT-protocol similar to ours in non-
pregnant rats. The CFR studies presented in Paper D were performed on the same rats 
presented in Papers A and B. 
3.1.1 Power analysis 
In order to comply with good ethical standards in animal research [83], we strived towards 
using as few animals as possible needed to give reliable results by doing power analyses 
before starting experiments. Assuming that following interventions eight out of ten rats will 
develop cardiac hypertrophy compared to less than one out of ten in the control group, we 
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calculated that nine animals are required in each experimental group to detect the effect of 
intervention at a significance level (alpha) of 0.05 with a power (beta) of 80%. In Paper C 
fewer rats than expected became pregnant after mating and the number of pregnant animals is 
smaller than predicted when designing the study (five and seven, respectively). .  
3.1.2 General considerations on animal models in pregnancy 
In all our studies we used young female rats aged 9-12 weeks at the start of experiments. Thus 
the rats were not fully grown and non-pregnant as well as pregnant rats continued to gain 
weight during the observation period. The animals were housed in cages in pairs under 
controlled conditions of temperature and humidity and light-dark periods of 12 h, and with 
free access to water and food. All rats (pregnant and non-pregnant) were fed a pellet diet 
especially produced for breeding rodents (Rat and Mouse NO.3 Breeding, Special Diet 
Services, Witham, Essex, U.K.) ad libitum and had free access to tap water. 
3.1.3 Mating and length of gestation 
In Papers A and B pregnant rats were obtained by mating with a male rat housed together with 
two female overnight for 12-18 hours. The rats where constrained in a cylindrical tube, an 
otoscope was inserted in the rat vagina and the presence of a vaginal sperm plug confirmed 
that copulation had taken place. The day of the vaginal plug was considered gestational day 
(GD) 0.5. Rats are naturally nocturnal animals, and since the training sessions for practical 
reasons had to take place in daytime, the circadian rhythm of the rats in Paper C was changed 
by reversing light/dark (12/12 hour) cycle. The rats were housed together with a male rat and 
mated at daytime for 6-7 hours, and the day of the mating was considered GD 0. In Paper C 
we experienced that fewer animals conceived after mating than in Papers A and B, both in 
HIIT and sedate rats. Thus the decreased pregnancy rate was not caused by decreased fertility 
in training rats, but probably related to a shorter time of pairing together with a male.  As the 
estrous cycle in rats is strongly influenced by light periodicity the reversed light/dark cycle 
applied in Paper C may also have affected the pregnancy rate negatively.  
The normal gestational length in the rat is 21-22 days. In Paper A the terminal experiments 
were performed at GD 18.5-20.5 in pregnant animals. However, fetal weight gain in the last 
few days of pregnancy is significant [84], and the mean body weight of the fetuses in each 
dam more than doubled from GD 18.5 (1.36±0.03 gram) to GD 20.5 (3.08±0.65 gram). Thus 
in Paper B and Paper C we strived towards doing all experiments at the same length of 
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gestation. In Paper B 20 out of 22 pregnant rats was examined at GD 20.5, one at GD 19.5 
and one at 21.5. Two rats delivered between GD 20.5 and 21.5 and were excluded from 
further analyzes. In Paper C all pregnant rats were examined at GD 20.  
3.1.4 Chronic angiotensin II infusion 
Increase in circulating AngII is a key component in the mechanisms behind pathological 
remodeling of the heart and thus inhibition of the response to AngII is essential in treatment 
of cardiovascular diseases [85-87].  AngII may induce heart remodeling through its direct 
effects on the heart and via increased afterload due to vasoconstriction in the systemic 
circulation [87-89]. In pregnancy the renin-angiotensin system (RAS) is upregulated leading 
to an increase in plasma concentrations of AngII [25, 90]. Even if the exact mechanism 
causing preeclampsia is not known, angiotensin receptor activation appears to drive the  
vascular maladaptation seen in pregnancy [91], pregnant women who subsequently develop 
preeclampsia appear to be more sensitive to infused AngII  [25, 92] and there is some 
evidence of AT1-AA playing an important part in the development of preeclampsia [48-54]. 
Thus the heart’s response to AngII in pregnancy is of particular interest.  
In Paper A heart hypertrophy was induced by implanting mini osmotic pumps (Alzet
®
 Model 
2002, Cupertino, CA, USA) releasing AngII subcutaneously. Before including pregnant 
animals, four different concentrations of AngII infusion (0, 150, 300 and 400 ng/kg/min) were 
tested in a total of 16 animals. The lowest rate of AngII infusion (150 ng/kg/min) that led to 
heart hypertrophy was chosen as a low concentration was considered closest to a 
physiological challenge, and higher concentrations of chronic AngII infusions may lead to 
cachexia without cardiac hypertrophy [89].  The pumps were implanted 9-10 days before 
terminal experiments, corresponding to GD 8.5-9.5 in pregnant dams. Mini osmotic pumps 
releasing saline were used in control animals (sham). Thus four groups were studied; non-
pregnant and pregnant sham, and non-pregnant AngII and pregnant AngII. 
3.1.5 Transverse aortic constriction 
Whereas Ang II may induce heart remodeling through direct effects on the heart as well as 
increased afterload, inducing LV outflow obstruction by mechanical constriction of the aorta 
will mimic the effects of purely increased afterload, as seen in aortic stenosis, co-arctation of 
the aorta or an interrupted aortic arch. 
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In Paper B the surgical procedure was performed on intubated and ventilated rats under 
general anesthesia with inhaled isoflurane (2.5% in 100% oxygen for maintenance). The rats 
were put in a closed chamber filled with 4% isoflurane in 100% oxygen (Vevo Compact 
Anesthesia System, VisualSonics, Toronto, Canada). The spontaneously breathing rats were 
fixated on a semi upright worktop hanging by the incisors on a tight string. Isoflurane was 
provided by a mask held over the snout to maintain anesthesia. The tongue was carefully 
pulled out by a pair of blunt tweezers and the vocal cords were visualized by pointing a bright 
light source at the external larynx. A 16G peripheral venous catheter with a shortened and 
blunted stylet used as mandrin was inserted in the rat trachea, the stylet was removed and the 
catheter was connected to a ventilator (New England Medical Instruments Inc., Medway, MA, 
USA) delivering tidal volumes of 2-3 ml at a frequency of 60 per minute. 2.5% isoflurane in 
100% oxygen was used to maintain the anesthesia. The rats were placed supine on a warm 
electric pad and the temperature was kept stable at approximately 38°C. The heart rate and the 
rectal temperature were monitored continuously. A heating lamp was used when required. 
Hair was removed with a mechanical shaver and application of depilatory cream (Vichy 
Laboratories, Paris, France). Surgery was performed under sterile conditions. Analgesia was 
provided with subcutaneous buprenorphine (Temgesic, Reckitt Benckiser, UK) 0.05 mg/kg 
and local bupivacaine (Marcain, AstraZeneca, Sweden). Pain reflexes were checked before 
surgery and concentration of inhaled isoflurane was increased if appropriate. After skin 
incision, the upper half of the sternum was divided in the midline using blunt scissors. Care 
was taken to remove the thymus in one piece, as in our experience this would reduce the risk 
of extensive bleeding.  In most cases satisfactory hemostasis could be obtained by applying 
gentle pressure with a sterile swab.  Then the aortic arch was carefully dissected free of the 
surrounding tissues. TAC was performed by tying a blunted and bended stylet from a 16G or 
18G IV catheter (Optiva, Smith Medical International Ltd., Rossendale, UK) tightly to the 
aortic arch between the brachiocephalic trunk and the left common carotid artery. When the 
stylet was removed, a partial constriction of the transverse aorta was created. In sham animals, 
the exact same procedure was performed; the aortic arch was lifted, but not tied. The 
sternotomy and the skin incision were closed with 5-0 sutures (Polysorb, Synture, Mansfield, 
MA, USA). The rats were extubated and put in an incubator (Vetario S10 Intensive Care Unit, 
Brinsea Products Ltd, N. Somerset, UK) at 28-30° C for the recovery period. Postoperatively 
they were kept in separate cages with free access to water and food. Analgesia with 
buprenorphine 0.05 mg/kg subcutaneously was provided every 12 hour for 48 hours. 
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Surgery was performed in a total of 57 rats. Four animals died during surgery. In three 
animals we were unable to control extensive bleeding from the vascular bed of the thymus or 
the internal thoracic arteries. In one rat the transverse aorta was tied completely without 
having the stylet in place and the animal developed acute heart failure and died of respiratory 
failure within minutes. Six animals died or were euthanized after surgery; three developed 
symptoms of acute heart failure (dyspnoea, cyanosis and hemoptysis), one respiratory distress 
due to pneumothorax, one stopped breathing shortly after extubation, probably related to drug 
overdose, and one was found dead in the cage. In the 47 surviving rats, there was no 
statistically significant difference in weight gain after surgery in TAC animals compared to 
sham animals. 
In the initial experiments we tested two sizes of TAC, using stylets from 16 and 18 G 
catheters. A total of nine rats had a tighter TAC using a stylet from an 18G IV catheter. Three 
of them developed symptoms of acute heart failure postoperatively and were euthanized, 
while this did not happen to any rats where the bigger stylet was used. Thus the less 
pronounced constriction was performed in the majority of animals. Two rats with a tighter 
aorta constriction were excluded due to inappropriate banding time, and two rats are included 
in each TAC group (pregnant and non-pregnant).  
We performed the surgery 14 (range, 13-17) days before terminal experiments, corresponding 
to GD 5.5-8.5 in pregnant rats, thus imitating hypertensive disorders of pregnancy. A longer 
period following TAC could have lead to more pronounced LV hypertrophy and overt heart 
failure [93], but the short duration of pregnancy in rats did not allow this.  
3.1.6 High intensity interval training 
Rats are used as an animal model in exercise in pregnancy for several reasons. The rat 
placenta is quite similar to the human placenta, rats adapt to training similar as humans do 
and, most importantly, rats appear to enjoy running [81]. Sprague-Dawley rats were subjected 
to high intensity interval training (HIIT) modified from a protocol originally described by 
Wisløff et al [94] and previously used in mice at our facility [39, 95].  
3.1.6.1 High intensity interval training in pregnant rats 
Five days/week one group of rats was subjected to exercise sessions of 10 bouts of 4 min high 
intensity treadmill running at 25° inclination separated by 2 min of treadmill running at low 
intensity (50-60% of the speed re uired to achieve estimated    2max).  Three or four rats ran 
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in parallel tracks on the same treadmill. Stimulation such as gentle physical handling, an 
airbrush or low current shock grids were used to secure high intensity. Usually the use of the 
shock grids was not necessary and painful stimulus was kept to a minimum. Contrary to 
described by Wisløff et al [94], rewarding the rats with chocolate was not effective in 
stimulating the rats to maximal effort. Speed was set in bouts of 85 to 90  of the speed 
re uired to achieve estimated    2max of rats at baseline, slowest in the first bouts of each 
session. Typically rats tolerated and achieved highest speed in the last bouts of each session. 
All rats were continuously monitored during the training sessions. Throughout the training 
period treadmill speed was increased gradually as long as the rats did not show signs of 
exhaustion.  
After 11-12 sessions of training, training was stopped for one day and one male rat was put in 
a cage with two female rats for 6-7 hours. The second day after mating, the rats resumed HIIT 
again. In pregnant rats, the day of mating was considered GD 0. HIIT was stopped 
corresponding to GD17-18 in pregnant rats out of concern for how the highly pregnant rat 
would perform on the tread mill and with regards to animal welfare as advised by the 
responsible veterinarian. The rats in the HIIT groups completed a total of 24 one hour 
sessions of HIIT with an average total running distance of 83±4 km per rat. Rats of the same 
age and size was kept as sedentary controls, pregnant and non-pregnant. 
3.1.6.2 Measuring maximal oxygen consumption in the rat 
 a imal o ygen consumption     2max) was measured in seven rats during the first days of 
training. The rats ran on a treadmill at 25° inclination in a metabolic chamber (Modular 
treadmill with Oxymax open circuit calorimeter, Columbus Instruments, OH, USA). Ambient 
air was pumped into the chamber at a fixed rate and samples of extracted air form the 
cham er were continuously analyzed for o ygen and car on dio ide. The speed was gradually 
increased until o ygen consumption leveled off despite increased running speed, and 
   2max was defined as    2 measured at this speed divided by rat weight [39, 94]. The 
treadmill velocity at    2max was used to set the speed of the treadmill for HIIT.    2max was 
measured again in the same rats after 11-12 training sessions, before mating. 
When running on a treadmill in a closed chamber, the rat is not accessible to physical 
stimulation except low current shock grids. We found it difficult to assure that the rats 
actually ran at their highest performance, and sometimes the rats would sit down on the low 
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current grid instead of running, even if     -measurements indicated that they was not 
running at their    2max . The estimated    2max varied considera ly.  efore training, mean 
   2max  was 78 (range 70-90) ml/kg/min, corresponding to a maximal running speed of mean 
1   range 1 - 1  m min. When    2max   was measured again after 11-1  training sessions 
mean measured    2max   was not increased,     range   -    ml  g min, while average speed 
at    2max   had increased by 16% to 22 (range 19-2   m min, indicating that that the 
   2max  measured did not detect an actual increase in physical performance. Thus    2max-
measurements were stopped after the first group of seven animals, and running speed in each 
session was set by the best judgment of the operator in the rest of experiments. 
3.2 Small animal echocardiography 
Echocardiography was performed using a high resolution ultrasound imaging system 
equipped with a RMV-710B transducer with a frequency of 25 MHz and a fixed focal length 
of 15 mm mounted on an integrated rail system (Vevo 770, Visualsonics, Toronto, Canada). 
Prewarmed ultrasound gel was used. The rats were anesthetized with isoflurane as previously 
described and silk tape (Leukosilk
® 
1.25cm, Smith&Nephew, London, UK) was used to fix 
the paws to the electrodes integrated in the plate provided with the ultrasound equipment. 
Conductance cream was used to secure good ECG signals. In Paper A the rats were 
spontaneously breathing 1.5-3.5% isoflurane in 100% oxygen provide by a mask over the 
snout. In Paper B and C the rats were intubated. 
In Paper A the studies were performed by two investigators, M.C.S. and N.T.S., and all 
analyzes were performed offline by M.C.S. N.T.S. did only studies on non-pregnant (Ang II 
and sham) animals in Paper A. In Paper B and C all studies were performed and analyzed by 
N.T.S. In Paper D, only CFR calculations performed and analyzed by M.C.S. were included 
from the Ang II-study and N.T.S. performed and analyzed all studies from the TAC-study.  
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3.2.1 Motion-mode echocardiography 
 
Figure 4 M-mode echocardiography from maternal left ventricle (LV) 
A. Parasternal short axis view through the LV anterior wall (AW), papillary muscle (PM) and 
LV posterior wall (PW). B. Measurement of LVAW, LV inner diameter (ID) and LVPW in 
diastole (d) and systole (s).   
Motion (M-) mode echocardiography recordings were obtained from the parasternal short- or 
long-axis views. All ultrasound based measurements were performed off-line without the 
 nowledge of the animals’ identity (Figure 4). Care was taken to select three consecutive 
cycles with good quality signals. The internal dimensions of the LV cavity and thickness of 
the anterior and posterior LV walls were measured. The heart rate (HR) was obtained from 
the electro-cardiogram signals. LV fractional shortening % was calculated as 100 x ((LVIDd-
LVIDs)/LVIDd) where, LVIDd = LV internal diameter in diastole and LVIDs = LV internal 
diameter in systole. Stroke volume (SV) was calculated as LV EDV – ESV where, EDV = 
end diastolic volume and ESV = end systolic volume. The LV EDV was calculated as 7.0/(2.4 
+ LVIDd)xLVIDd
3 
and the LV ESV was calculated as 7.0/(2.4 + LVIDs)xLVIDs
3
 [96]. 
Cardiac output per minute (CO) was calculated as SV x HR. Relative wall thickness (RWT) 
was calculated using the formula: RWT = (LVPWd + LVAWd )/LVIDd where, LVPWd= LV 
posterior wall thickness and LVAWd = LV anterior wall thickness. LV mass was calculated 




 [97].   
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3.2.2 Coronary flow reserve 
Coronary flow reserve (CFR) is used as a measure of coronary endothelial function. In the 
AngII- and TAC-studies, Doppler echocardiography was used to measure velocities in 
coronary artery and thus calculating CFR. This method is described in detail and evaluated in 
Paper D. In short, high concentrations (3.5%) of inhaled isoflurane were used as a 
vasodilating agent and were compared to the standard dose (1.5%) of isoflurane used to 
maintain anesthesia in rats not exposed to painful stimuli. CFR was calculated as the ratio 
between the peak coronary flow velocities (CFRpeak) and the velocity-time integrals (CFRVTI) 
recorded at hyperemia (3.5%) and at baseline (1.5%). 
3.2.3 Doppler echocardiography  
Doppler echocardiography was performed in the AngII-study. Ejection time (ET), 
isovolumetric relaxation time (IRT), isovolumetric contraction time (ICT) and Tei-index was 
calculated from pulsed-wave Doppler signals from the LV inflow and outflow recorded 
simultaneously as following: ET, ejection time (total time of LV outflow). IRT, time from the 
end of LV outflow signal to start of the mitral flow signal. ICT, time from the end of mitral 
flow signal to the start LV outflow signal.  Tei-index = (ICT+IRT)/ET [98]. Mitral valve E/A-
ratio is the ratio of the early (E) to late (A) LV peak filling velocities. Results are presented in 
Appendix 1.  
In the TAC-study we planned to evaluate the size of the banding and estimate the pressure 
gradient across the banding by B-mode and Doppler echocardiography. However, in most 
animals we were not able to visualize the banding site satisfactory, possibly due post-
operative scaring. Color Doppler mode may have been useful in locating the constriction and 
thus facilitating obtaining useful measurement, but this was not available in the ultrasound 
machine used (Vevo 770) when these studies were performed. 
3.2.4 Fetal echocardiography 
In the AngII-study fetal echocardiography was performed in 126 fetuses in 29 dams. Data 
from two AngII-treated rats was excluded due to fetal bradycardia indicating that the rats 
were hemodynamically unstable during the experiment. Thus ultrasound measurements from 
a total 119 fetuses from 27 animals (12 AngII and 15 sham) were included. E/A-ratio, ICT, 
IRT and Tei-index [98] were calculated from fetal mitral flow signals. Doppler flow velocity 
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waveforms were obtained from the umbilical artery, ductus venosus and ductus arteriosus and 
the pulsatility index (the difference between peak systolic and minimum diastolic velocities 
divided by time-averaged maximum velocity) was calculated for all vessels. Results are 
presented in Appendix 2.  
3.3 Intravascular blood pressure measurements and pressure-volume 
analysis of the rat heart 
In the AngII- and TAC studies a 2F microtip pressure-volume (PV) catheter (SPR-838; Millar 
Instruments Inc, Houston, TX, USA) was inserted via the right carotid artery into the 
ascending aorta and through the aortic valve into the LV. The procedure was performed 
immediately after echocardiographic examinations (Figure 5A). Pain reflexes were checked 
and isoflurane concentrations increased as appropriate. Sharp scissors were used to cut 
through the skin and platysma muscles and trachea was identified (Figure 5B). The right 
carotid artery and vagus nerve was carefully dissected free, lifted up and split apart (Figure 
5C). A micro vascular clamp was fixed to the proximal artery (Figure 5D) and the distal part 
of the artery was tied by sutures an externally fixated. A bend needle of an insulin syringe 
(Figure 5E, Omnican
®
, B. Braun Medical AG, Melsungen, Germany) was used to perforate 
artery and keep the perforation open as the catheter was introduced. Two sutures were tied 
tightly around the artery and the catheter to prevent bleeding as the clamp was removed and 
the catheter advanced into the carotid artery and ascending aorta (Figure 5D). Aortic BP was 
measured before the catheter was introduced into the LV. The PV-signal was recorded by a 
PowerLab using a LabChart 7 acquisition system (AD Instruments) and was used to verify 
proper position of the catheter in the LV (Figure 5F). The animal was allowed to stabilize 
before the baseline PV-loops were recorded. In Paper B PVAN 3.6 software (Millar 
Instruments Inc) was used to analyze PV-loop data. 
Raw signals from volume measurements were calibrated with SV calculated from M-mode 
echocardiography. Mean arterial pressure (MAP) was calculated as 2/3 x diastolic BP + 1/3 x 
systolic BP, total peripheral resistance (TPR) as MAP divided by CO, and LV stroke work 
was calculated as the difference between maximum and minimum LV pressure multiplied 
with SV. Effective arterial elastance (Ea) was calculated as the ratio of LV end-systolic 
pressure to SV. dP/dtmax, dP/dtmin and isovolumetric relaxation constant (Tau) were calculated 
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by the software. LV end-systolic  elastance (Ees) was calculated as the ratio of end systolic   
pressure to ESV. 
 
Figure 5 Pressure-Volume loop recording from the left ventricle of a rat 
Insertion of conductance catheter via right carotid artery (A-E) and screen capture of PV-
loop recordings from LV (F). 
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In Paper B the right carotid artery was cannulated in three rats to measure the pressure 
gradient across the aortic constriction. However, these rats became clinically unstable (drop in 
BP, cyanosis, bradycardia) shortly after catheter placement, and thus we refrained from 
bilateral catheter placement in the majority of animals.  The cardiovascular deterioration 
associated with bilateral catheter placement may be related to cerebral ischemia or direct 
effects on vascular baroreceptors.  
3.4 Morphometry 
Rats were weighed and body weight (BW) determined before terminal experiments were 
performed, immediately before anesthesia. In the end of terminal experiments, the rats were 
euthanized with sodium pentobarbital 100 mg/kg administered intravenously or 
intraperitoneally. The hearts were excised immediately, washed in phosphate-buffered saline 
(PBS) or 0.9% NaCl and dried rapidly on a piece of gauze before it was weighed (HW). In the 
TAC- and HIIT-studies the LV was dissected free from the right ventricle, the atria and the 
mitral and tricuspid valves, and weighed (LV weight) and the right tibia was dissected free 
and measured with calipers. Which parameter best describes cardiac hypertrophy in 
pregnancy remains controversial. Conventionally used parameters include HW, LV weight 
and HW/BW-ratio. As maternal BW increases with advancing gestation, use of HW/tibia ratio 
[99] may be better than HW/BW ratio in pregnancy and was therefore used in Papers B and 
C. The fetoplacental units were removed from the uterus and put in a petri dish filled with 
PBS or 0.9% NaCl. Placentas and fetuses were dissected free, gently dried on gauze and 
weighed and crown-rump length (CRL) was measured without actively extending the fetus. 
The fetus was put back into the petri dish and the thoracic cavity cut open and the fetal heart 
was removed using a pair of bended sharp tweezers. A magnifying glass was used to ascertain 
that the tissue collected was from the heart as liver or lung tissue can easily be mistaken for 
heart tissue in small fetuses. Fetal hearts were put on individually preweighed eppendorf tubes 
filled with tissue storage reagent (RNAlater
®
, Qiagen, Hilden, Germany) and fetal heart 
weight was calculated as the difference of weight of the tubes before and after.  
3.5 Histology 
Myocardial tissue samples were taken from the LV and fixed in formalin. Slides stained with 
Toluidine Blue were used for the measurement of cardiomyocyte size, Sirius Red staining was 
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used for quantification of collagen content and β-actin immunolabeling for vessel density 
calculation. 
3.5.1 Cardiomyocyte size 
In the AngII-study pictures were taken using a Leitz Aristoplan microscope with a Leica 
DFC320 digital camera (Leica Microsystems Digital Imaging, Cambridge, United Kingdom). 
Minimum myocyte diameter at the level of the nucleus was measured using computer based 
morphometry (Leica CTR 600 & Leica Qwin V3, Leica Microsystems, Wetzlar, Germany) on 
a minimum of thirty cells in each heart. Only cells with visible nucleus were used for 
quantification. In the TAC-study a Leica DM2000 microscope was used for viewing slides, 
and sixteen photographs from each slide were taken with a Leica DFC 425 digital camera. 
97±7 cardiomyocytes cut in short axis and containing a nucleus were identified from each 
heart. Cell circumference was outlined digitally using Image J (National Institutes of Health, 
Bethesda, MD, USA) and the myocyte transverse circumference was expressed in arbitrary 
units (Paper B, Figure 3).  In the HIIT-study we refrained from doing microscopic studies of 
tissues as there were no significant changes in gross measurement, cardiac function as 
measured by ultrasound or expression of any mRNAs related to heart hypertrophy. 
3.5.2 Fibrosis and collagen content in heart tissue 
Collagen content was analyzed in the AngII- and TAC-studies. Formalin-fixed sections of the 
left ventricle were paraffin embedded and sliced, and Sirius Red staining of collagen fibers 
(Direct Red 80, Sigma-Aldrich, Germany) was performed. In the AngII-study transverse 
ventricular sections were examined under microscope using conventional and polarized light 
at magnification 50x and 200x. The level of staining as well as tissue changes and injury was 
evaluated and scored by an experienced pathologist (dr. Samer Al-Saad), who was blinded to 
information about AngII or pregnancy status. Each heart was finally assigned to one category 
with respect to collagen content and also scored according to presence of necrosis or not. The 
results are presented in Paper A, Table 4. In Papers A and B myocardial collagen content was 
measured in a minimum of 20 (Paper A) or 16 (Paper B) sampled images (200x) from each 
heart. Image J was used to analyze % tissue area stained by Sirius Red as described online by 
the developer [100]. Perivascular areas (containing higher concentrations of extracellular 
collagen) were outlined using Image J and excluded from quantification. As we did not expect 
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pathological accumulation of collagen in HIIT, we did not quantify collagen content in this 
study.  
3.5.3 Vessel density in left ventricular myocardium 
In Paper A angiogenesis was evaluated by estimating vessel density in hearts by 
immunohistochemistry using non-muscular β-actin to identify endothelial cells [101, 102]. 
Staining was performed using primary antibody against non-muscular β-actin protein (mouse 
anti rat, Beta-Actin; clone AC-74, Sigma). The slides were counterstained with haematoxylin 
to visualize the nuclei. Sections were examined under light microscope at 200x and twelve 
pictures of each heart section were taken from the left ventricle from four different areas. 
Using Image J software, a grid of 80 points (area per point was 3.22 cm
2
) was applied on each 
picture and relative vessel density was expressed as the number of points crossing a blood 
vessel. 
3.6 Gene expression in tissues 
Gene expression analysis was performed to study changes induced by pregnancy or 
experimental interventions (AngII infusion, TAC or HIIT). Real time polymerase chain 
reaction (RT-PCR) was used to quantify expression of genes in maternal myocardium, 
placenta and fetal heart and liver. In all studies presented, relative quantification was used. 
Tissue was stored in RNA later (Qiagen, Hilden, Germany) and the samples were 
homogenized and lysed and total RNA was isolated according to the RNeasyFibrous Tissue 
protocol (Qiagen). RNA concentration was measured by spectroscopy (NanoDrop, Witec, 
Switzerland), and stored at - 80 °C before use. Reverse transcription of RNA was carried out 
according to High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems, Foster 
City, CA, USA). The qualitative RT-PCR was performed in an ABI PRISM 7900 HT Fast 
real-time thermal cycler using the SYBR green or TaqMan Fast Universal PCR master mix 
(Applied Biosystems). The relative expression ratio of the target gene was calculated based on 
its real-time efficiency and threshold cycle differences between groups. The expression of the 
target genes were normalized to the stably expressed reference gene based on testing by 
Norm-Finder (Aarhus University Hospital, Aarhus, Denmark) of possible reference genes 
[103]. The presented data is normalized to controls. The reference genes and primers used are 
presented in Appendix 5. In fetal heart, the expression of Ddx3y (DEAD box polypeptide 3, 
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Y-linked) and Eif2s3y (eukaryotic translation initiation factor 2, subunit 3, Y-linked) was 
used to different male from female fetuses. 
3.7 Oxidative stress and total antioxidant capacity 
In Paper C level of oxidative stress and total antioxidant capacity was measured in placentas 
and fetal hearts and livers. Decreased total antioxidant capacity and increased level of 
malondialdehyde (MDA) together with the decreased superoxide dismutase (SOD) and 
peroxidase activities are indicators of oxidative stress. 
Frozen tissue samples from 2-3 feto-placental units from each dam was thawed, weighed and 
homogenized for 2-3 min with a mechanical homogenizer in the buffer supplied in the assay 
kits to prepare 50 mg/ml suspensions. The homogenized suspension was checked with light 
microscope and centrifuged to 14000 x g for 15 min at 4° C. The supernatant was separated 
and stored in working aliquots at -70° C. All analyses were performed on the supernatant 
according to the instructions provided by the manufacturers of the assay kits. 
3.7.1 Malondialdehyde level 
MDA content was quantified by using OxiSelectTM TBARS Assay kit (Cell Biolabs, Inc., 
San Diego, CA, USA). All samples and standards were assayed in duplicate. The 
thiobarbituric acid reaction was completed in a microcentrifuge tube (1.5 mL) at 95° C for 1 
hour. 200 µL of the reaction product was transferred into a 96 well microplate and the color 
was read with a spectrophotometric plate reader at 532 nm using blank as control. 
3.7.2 Superoxide dismutase activity  
SOD activity was carried out by using the procedure as provided with the SOD activity assay 
kit (Abnova GmbH EMBLEM, Heidelberg, Germany). This assay kit measures total (both 
cytosolic and mitochondrial) SOD activity and the results are reported as inhibition rate %. 
All reactions were carried out in a 96 well microplate in triplicate, and the absorbance was 
read at 450 nm using a microplate reader.  
3.7.3 Peroxidase activity  
Peroxidase activity reactions (Sigma-Aldrich, St. Louis, MO, USA) were carried out in a 96 
well microplate in quadruplet, and the absorbance was read at 570 nm. 
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3.7.4 Total antioxidant capacity 
Cumulative antioxidant capacity was quantified using an antioxidant assay kit (Sigma-
Aldrich, St. Louis, MO, USA). All reactions were carried out in 96 well microplate in 
duplicate. The absorbance was read at 405 nm using a microplate reader and the results are 
presented as the inverse of optical density readings. 
3.8 Data analysis and statistical methods 
All measurements and analyzes were performed without the knowledge of pregnancy status 
and intervention. For obvious reasons the operator could not be blinded for pregnancy status 
when performing echocardiography, inserting PV-catheters and collecting tissue samples. 
However, echocardiograhy and PV-data were analyzed off-line with the investigator blinded 
to the allocation of experimental groups.  
All data are reported as mean±standard error of the mean (SEM). A p-value 0.05 was 
considered statistically significant. Logarithmic transformation was used to achieve normal 
distribution of continuous variables when appropriate. As fetoplacental units from the same 
mother should not be handled as independent units, mean values for each mother was used 
when analyzing effects of interventions on pregnancy outcome (biometry, fetal 
echocardiography, oxidative stress and RT-PCR). Correlation between parametric variables 
was checked using Pearson Correlation coefficient. Categorical data comparison between 
groups was performed using chi-square test. Independent-Samples T-test was used to compare 
two groups. One way analysis of variance (ANOVA) was used to compare the 4 groups of 
rats. Two way ANOVA was used to investigate the influence and interaction between 
pregnancy status and interventions (AngII, TAC or HIIT) and the influence and interaction 
between fetal sex and interventions on gene expression in fetal tissues. Only differences in 
influence without significant interaction between pregnancy and TAC are presented for two 
way ANOVA. The Holm–Sidak method was used as post-hoc test. Sigma Plot 12.0 (Systat 
Software Inc, San Jose, CA, USA) software was used for two way ANOVA and PASW 






In this section the results from Papers A-D are summarized and some supplementary data are 
presented.  
Paper A: Pregnancy protects against antiangiogenic and fibrogenic effects 
of angiotensin II in rat hearts 
4.1 Summary of the results  
The effects of chronic AngII infusion on pregnant and non-pregnant Wistar rats were 
compared to infusion of 0.9% NaCl (sham). AngII infusion for 9-10 days led to an increase in 
diastolic and systolic BP compared to sham, while pregnancy status did not significantly 
influence BP. Heart weight and LV relative wall thickness were higher in pregnant AngII 
infused rats compared to AngII infused non-pregnant rats, pregnant sham and non-pregnant 
sham. Myocyte diameter was not affected by AngII or pregnancy. Ejection fraction was 
higher in AngII infused pregnant rats than in non-pregnant and pregnant sham. AngII infusion 
resulted in an increase in collagen content, and pregnancy ameliorated this effect. Vessel 
density in LV was decreased in AngII infused compared to sham non-pregnant rats, but not 
significantly decreased in pregnancy. AngII infusion led to significant changes in LV 
expression of genes related to function, fibrosis and apoptosis, with an increase in ANF, BNP, 
ANKRD1, PKCα, PKCδ and TP  . Pregnancy itself did not induce increased e pression of 
known markers of pathological remodeling,  ut reduced the e pression of α- HC, TNFα, 
TP53, eNOS and iNOS. Fetal size, placenta weight or litter sizes were not influenced by 
AngII infusion. 
We concluded that pregnancy and chronic exposure to a moderate dose of AngII has 
contrasting effects on fibrosis and angiogenesis in the heart. Pregnancy seemed to counteract 
the detrimental effects of AngII on fibrosis and angiogenesis in heart despite synergistic 
effects with respect to heart hypertrophy. Pregnancy and AngII lead to partly opposite 
changes in the expression of some of the genes related to heart function and remodeling. 
4.1.1 Supplementary data  
Data presented in Paper A are from six randomly selected rats from each group; Sham, 
Pregnant, AngII and Pregnant Ang II. Supplementary echocardiographic measurements from 
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all rats are presented in Appendix 1. Calculations derived from B-mode echocardiography 
were not significantly affected by pregnancy or AngII infusion. 
Fetal echocardiography was performed on a total of 126 fetuses in 29 dams. Results are 
presented in Appendix 2. There were no significant differences between any of the measured 
variables.  
Expression of genes in fetal hearts from pregnant rats infused with AngII and sham rats is 
presented in Appendix 3. Expression of genes is normalized to fetuses from sham rats and 
mean values of fetal hearts (n=2-3) from each dam is calculated. Fetal sex did not 
significantly affect gene expression in fetal heart (data not presented). 
 Paper B: Effect of transverse aortic constriction on cardiac structure, 
function and gene expression in pregnant rats 
4.2 Summary of the results  
The effect of increased afterload on the heart was studied ~2 weeks after TAC in non-
pregnant and pregnant Wistar rats. Aortic systolic, but not diastolic BP was increased by 
TAC. Diastolic BP was decreased in pregnant compared to non-pregnant sham operated rats. 
TAC for ~2 weeks did not lead to overt heart failure. Heart weight and LV weight was 
increased by TAC, but not by pregnancy. Ejection fraction or cardiac output was not 
influenced by pregnancy or TAC.  Stroke work in pregnant TAC rats was double compared to 
pregnant shams, whereas it was only 35% higher (not significant) in non-pregnant TAC rats 
compared to non-pregnant shams. Myocyte transverse circumference was increased by 
pregnancy, but not by TAC. Nine out of the 19 genes examined related to cardiac remodeling 
were affected by pregnancy independent of TAC.  The increase in expression of β-MHC was 
higher in pregnant (5-fold) compared to non-pregnant rats (2-fold) after TAC, and the ratio of 
β-MHC to α-MHC expression was higher in pregnant TAC compared to non-pregnant TAC. 
Myocardial tissue collagen was not influenced by pregnancy or TAC, but expression of 
fibrosis related genes (COL3A1, COL1A1, FN1 and TIMP1) was up-regulated by TAC. Fetal 
size, placental weight and litter sizes were not influenced by TAC. 
In conclusion this study demonstrated that pregnancy per se does not lead to significant 
cardiac hypertrophy in Wistar rats and does not protect against the negative effects of 
increased afterload caused by TAC. The differences in cardiac structure, function and gene 
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expression between pregnant and non-pregnant rats following TAC indicated that increased 
afterload may be less tolerated in pregnancy. 
4.2.1 Supplementary data  
Gene expression in fetal hearts from TAC and sham operated pregnant rats is presented in 
Appendix 4. Expression of genes is normalized to female sham fetuses and mean values of 
two fetal hearts from each dam is calculated. Fetal sex did not significantly affect gene 
expression in fetal heart (data not presented). 
Paper C: High intensity interval training in pregnant rats alters gene 
expression in fetal heart and liver without inducing oxidative stress 
4.3 Summary of the results   
We studied the effects of six weeks of HIIT on the heart, placenta and fetuses of Sprague-
Dawley rats. HIIT was well tolerated by pregnant rats. HIIT for six weeks or pregnancy did 
not lead to significant heart hypertrophy. Myocardial expression of 22 genes related to cardiac 
remodeling was not influenced by HIIT, but the expression of 11 of these genes was 
decreased in the myocardium of pregnant compared to non-pregnant rats. Fetal and placental 
growth or litter size was not affected by HIIT. Oxidative stress (peroxidase and superoxide 
dismutase activity and malondialdhyde level) and total antioxidant capacity in placenta, fetal 
liver and fetal heart was not influenced by HIIT, and HIIT did not alter the expression of 
genes related to oxidative stress in the placenta. However, HIIT reduced the expression of 
eNOS, HIF1A and GPx4.2 in the fetal liver and increased the expression of VEGF-β, SOD1 
and TIMP3 in the fetal heart. Total antioxidant capacity was higher in fetal liver than in fetal 
heart and placenta independent of HIIT, suggesting that the placenta and developing heart are 
more vulnerable to oxidative stress compared to liver. 
We concluded that HIIT is feasible in pregnant rats, but HIIT for six weeks did not lead to 
cardiac remodeling. There were no obvious adverse effects of HIIT in pregnancy on the 
mother. Fetal and placental growth as well as the level oxidative stress and total antioxidant 
capacity in placenta, fetal heart and liver were not affected by HIIT. However, some genes 
related to oxidative stress were altered in the fetal heart and liver indicating that adaptive 
mechanisms are activated.  
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Paper D: Coronary flow reserve in pregnant rats with increased left 
ventricular afterload 
4.4 Summary of the results  
We evaluated a Doppler echocardiographic method to non-invasively measure CFR in rats 
using different concentrations of inhaled isoflurane. High concentration (3.5%) of inhaled 
isoflurane was used as a coronary vasodilator. CFR was measured in the same pregnant and 
non-pregnant rats that were used in AngII and TAC studies. We found that CFR can be 
measured non-invasively in rats using this technique. We were able to calculate CFR using 
Doppler flow velocity waveforms of LMCA in most animals. CFR was reduced in pregnant 
rats compared to non-pregnant. CFR was not significantly affected by AngII infusion for ~10 





5.1 Study design 
In Papers A, B and C we used a similar design where an intervention (AngII, TAC or HIIT) 
was applied to pregnant and non-pregnant animals. Thus we had four groups of rats of same 
sex, similar age and size for studying the effects of both the pregnancy and the intervention. 
This simple study design reduces confounding to a minimum as all rats are as equal as 
possible except for the intervention and pregnancy status. We are aware of only a few other 
experimental studies in pregnancy that has used a similar design [104-107]. In most previous 
studies non-pregnant animals has been compared to pregnant animals [6, 7, 33, 108-114], 
pregnant control animals have been compared to pregnant animals subjected to an 
intervention [54, 63, 92, 115, 116] or both [117]. In some studies pregnant animals have been 
compared to non-pregnant animals subjected to an intervention [33, 40, 63, 118]. To illustrate, 
in one frequently cited study of physiological hypertrophy, pregnant mice were compared to 
non-pregnant mice and to male mice subjected to TAC [33], thus not taking possible effects 
of gender and differences in size into account. In addition to minimizing confounding, our 
study design enabled us to determine if changes in structure, function or gene expression can 
be attributed to pregnancy, intervention, or both, allowing us to get reliable data using a 
relative small sample size. We found this design particularly advantageous when analyzing 
gene-expression data using two-way ANOVA as a statistical method for comparing groups. 
Reducing the unnecessary use of animals is important when performing research on animals 
for animal welfare reasons [83], as well as out of obvious economical and practical 
considerations.  
5.2 Physiological effects of pregnancy on the heart in the rat 
In all three studies we included groups of non-pregnant and pregnant control animals. Thus 
we could evaluate the effects of pregnancy per se on the heart, as well as the effects of the 
interventions applied (AngII infusion, TAC or HIIT).  
5.2.1 Pregnancy does not lead to significant heart hypertrophy in rats 
It is widely believed that pregnancy causes physiological cardiac hypertrophy characterized 
by chamber enlargement without any increase in LV wall thickness/chamber diameter ratio 
[2, 22, 33, 40, 119, 120] (Figure 1). Pregnancy leads to significant heart hypertrophy in 
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humans [2, 9, 119, 120]  and mice [7, 33, 40], and some authors have previously reported 
increased cardiac mass in pregnant rats [108-110, 118]. Thus, when planning and designing 
the first (AngII) study we expected to find evidence of physiological heart hypertrophy in 
pregnant as well as AngII infused rats. Interestingly, we did not find any evidence of 
significant heart hypertrophy in pregnant compared to non-pregnant control animals in any of 
the presented studies. 
Total HW, LV weight and HW/BW-ratio are conventionally used parameters of heart 
hypertrophy. As BW increases with advancing gestation, use of HW/tibia ratio [99, 118] may 
be better than HW/BW ratio. However, none of the parameters measured supported the 
evidence of significant cardiac hypertrophy in pregnant Wistar (Paper A and Paper B) or 
Sprague Dawley rats (Paper C). These findings are in contrast to some other studies 
performed in rats. Jankowski et al. found a 28% increase in both HW and LV weight in 
pregnant Sprague-Dawley rats at GD21 (n=8 in each group, age not reported) [109], and 
Rimbaud et al. found an increase in both HW and HW/tibia-ratio of 10% in nine pregnant 15-
weeks old Wistar rats at GD18-19 compared to in ten non-pregnant rats [118]. Virgen-Oritz et 
al. report an increase in HW/BW-ratio from 3.69 in non-pregnant (n=8) to 4.34 in pregnant 
(n=8) Sprague-Dawley rats at GD18-21 without providing actual weight [110]. This is in 
contrast to ours as well as others [109, 118] findings of decreased HW/BW-ratio in pregnant 
rats. Gonzalez et al. [108] report an increase of 70 % in LV mass calculated using 
echocardiography in pregnant compared to non-pregnant Sprague-Dawley rats. However, 
uncertainty in morphological data presented for five rats in each group make their conclusions 
questionable as the HW (89 – 95 g) and LV weights (78 – 93 mg) presented appear way out of 
range for adult, female rats. The TAC-study had an 80% statistical power to detect an increase 
in HW of 13%. When all pregnant (n=24) and non-pregnant (n=18) sham animals from the 
AngII- and TAC-studies were pooled together there was still no difference in HW between 
groups (730±20 vs 700±14 mg, p=0.24). We are not aware of studies in rats that report 
increased cardiac mass in pregnancy with equally high number of pregnant animals included. 
In support of our findings, Buttrick et al did not find increased heart weight in pregnant 
compared to non-pregnant 12-14 weeks old Wistar rats (eight rats in each group) [6], and 
Bassien-Capsa et al even report a significant decrease in wet heart weight in 13-14 weeks old 
pregnant Sprague-Dawley rats (n=17) compared to non-pregnant (n=19). Dry heart weights 
were similar in pregnant and non-pregnant animals. Both Buttrick and Bassien-Capsa refrain 
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from discussing the lack of hypertrophy in pregnancy further in their papers [6, 117]. 
Interestingly LV wall thickness measured with M-mode echocardiography was increased in 
pregnancy in the same rats [117]. In both studies reporting increased LV wall thickness in 
pregnant rats using ultrasound, the authors do not report if the investigators performing 
echocardiography or performing offline measurements were blinded to rats pregnancy status 
[108, 117]. Thus one may suspect overestimation of the LV mass in pregnant rats (error of 
anticipation) using echocardiography. 
In humans, pregnancy is associated with an increase in blood volume leading to an increase in 
preload and the LV end-diastolic volume [14, 15, 17, 18]. Increased filling of the heart leads 
to increased SV and CO. However, in the TAC-study LV internal diameter in diastole and LV 
end-diastolic pressure were not increased in pregnant sham rats indicating that preload is not 
increased in pregnancy in rats. Slangen et al used electromagnetic flow probes around 
ascending aorta to show that pregnancy increased CO in pregnant Wistar rats. Heart weights, 
or any other measures of hypertrophy were not reported [121]. Studies in mice indicates that 
there is a good correlation between measurements obtained by flow probes and 
echocardiography [122]. However, our studies did not detect differences in CO between 
pregnant and non-pregnant control animals using M-mode echocardiography. Lack of an 
increase in CO in pregnancy may explain why the heart size was not increased by pregnancy 
in our studies on rats. High estrogen levels in pregnant animals may also be responsible for 
this, as in a recent study by Pedram et al [123] estrogen is shown to prevent cardiac 
hypertrophy in cultured neonatal rat cardiomyocytes via the estrogen receptor-β.  
In general, concentric cardiac hypertrophy due to increased afterload on the LV is associated 
with a greater increase in cardiac myocyte width compared to length,  whereas eccentric 
cardiac hypertrophy is associated with an increase in myocyte length [29, 35] (Table 1). Thus 
increased myocyte size in pregnancy has been attributed to increased myocyte length [33, 
110]. In the AngII-study there was no difference in cardiomyocyte diameter and in the TAC-
study there were no significant difference in cardiomyocyte transverse circumference between 
pregnant and non-pregnant sham rats. However, in the TAC-study the myocyte circumference 
was increased in pregnancy when the analysis was performed on all rats independent of TAC-
status (two way ANOVA, p=0.01). Reliable measurements of myocyte length are not possible 
to obtain using histological sections of LV myocardium. To explore this aspect of heart 
hypertrophy at the cellular level, single myocytes should be examined [110, 117]. As 
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pregnancy per se did not lead to cardiac hypertrophy in rats in our studies, and there was no 
echocardiographic evidence of LV dilatation (similar LV inner diameter in diastole in all 
studies) studies on single myocytes were not done. Bassien-Capsa et al report a small (113.4 
vs 117.5 µm) but significant difference in myocyte length between the hearts of pregnant and 
nonpregnant rats. However, as the statistical analysis was performed on the single cell level, 
and not on individual animal level this result remains questionable. In our opinion, statistics 
should be performed on mean myocyte length from each rat as individual single cells from the 
same heart should not be regarded as independent. 
The lack of significantly increased heart mass in pregnant rats was surprising, but was 
reproduced in all three studies. Echocardiographic measurements have several limitations, but 
the accuracy of the HW and LV weight should be indisputable. Thus we conclude that 
pregnancy does not lead to a significant increase in heart mass in rats, and we would advise 
against using pregnant rat as an experimental model of physiological heart hypertrophy. 
5.2.2 Heart function and pregnancy 
In all studies echocardiographic evaluation of heart function was performed measuring LV 
fractional shortening and ejection fraction. SV and CO output were calculated from M-mode 
echocardiographic measurements. In AngII-study, the evaluation of heart function was 
supplemented with indices of mitral valve blood flow velocity signals (Appendix 1). In Paper 
B we presented pressure-volume data obtained from pregnant and non-pregnant sham 
operated animals. The only significant difference in any measure of cardiac function between 
pregnant and non-pregnant control rats was a decreased dP/dtmax in pregnant (7.7±1.1 
mmHg/sec*10
3
) compared to non-pregnant (10.9±0.7 mmHg/sec*10
3
) animals in the TAC-
study (Paper B, Table1). dP/dtmax is used as a measure of LV systolic/contractile function, and 
is highly dependent on both preload and afterload [124]. Thus, a significantly lower dP/dtmax 
may also be explained by a lower BP in pregnancy (Paper B, Figure 2) rather than reduced 
contractile function. 
The data on how pregnancy influences heart contractility is conflicting. In a longitudinal 
study of healthy, pregnant women Gilson et al used M-mode echocardiography to 
demonstrate enhanced myocardial performance in late gestation pregnancy compared to early 
pregnancy and post-partum [5]. In contrast, Clark et al did not find any significant difference 
in LV function when central hemodynamic measurements (pulmonary artery catheterization 
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and arterial line placement) were performed at 36-38 weeks gestation and 11-13 weeks post 
partum [8], and Geva et al found a transient decrease in contractility in the second trimester 
using serial echocardiographic measurements during and after pregnancy [9]. As described in 
the introduction heart function in pregnancy is vastly influenced by the variability in the 
loading conditions in pregnancy [9-11]. In clinical studies as well as in in vivo animal studies, 
it is not possible to correct for all parameters influencing pre- and afterload in pregnancy. 
However, in the isolated working heart both pre- and afterload can be tightly controlled and 
neuroendocrine influences neutralized [6, 125]. Buttrick et al found an increased contractile 
performance in isolated rat hearts of third trimester pregnant rats, compared to controls, 
whereas cardiac contractility was not significantly improved in the heart of first trimester or 
postpartum rats [6]. Data from our studies could not underpin these findings. More studies on 
the isolated hearts of pregnant animals might prove to be valuable when exploring the effects 
of pregnancy on cardiac function and metabolism. Since we did not detect cardiac 
hypertrophy in pregnant rats, mouse models may be more appropriate [126]. 
5.2.3 The coronary circulation and pregnancy 
Coronary flow reserve (CFR) calculated from Doppler measurements of LMCA flow 
velocities at low and high concentrations of inhaled isoflurane in the AngII and TAC-studies 
are presented in Paper D. In the TAC-study CFRpeak was significantly reduced in pregnant 
compared to non-pregnant sham operated rats (Paper D, Figure 2C). The same trend was 
observed for CFRVTI in the TAC-study (Paper D, Figure 2D) and in sham treated rats in the 
AngII-study. Combining data on sham animals from two studies, we found that both CFRpeak 
and CFRVTI were significantly lower in pregnant compared to non-pregnant rats (Paper D, 




Figure 6 Coronary autoregulation, blood pressure and coronary flow reserve 
Coronary flow is determined by coronary perfusion pressure. It is regulated by coronary 
vascular resistance and will remain relatively constant over a wide range of perfusion 
pressures. When high doses of inhaled isoflurane are administered, the vessels of the 
coronary bed are maximally dilated (corresponding to the upper dotted line) and the 
autoregulation is revoked. Thus the calculated CFR is directly dependent on the coronary 
perfusion pressure. Adapted from Baumgart et al [127]. 
Flow mediated vasodilatation (FMD) is believed to reflect the endothelial function in the 
peripheral resistance vessels but may not correlate with that of the coronary vascular bed [70, 
78, 79, 128]. Studies in pregnant women have shown that FMD decreases towards term [72, 
73, 76] which is in line with our findings. The coronary circulation is subjected to 
autoregulation and coronary blood flow is constant over a wide range of pressures [80, 129] 
(Figure 6). When the vascular bed of the heart is maximally vasodilated (e.g. by adenosine or 
isoflurane) the coronary autoregulation is revoked and coronary blood flow exhibits a linear 
relationship with the myocardial perfusion pressure [80, 127]. As coronary flow is 
predominantly diastolic in the rat LMCA (Paper D, Figure 1BC), an increase in diastolic BP 
may increase calculated CFR. Therefore, the reduced CFR in late pregnancy may be a result 
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of reduced diastolic BP rather than impaired coronary endothelial function in healthy 
pregnancy (Figure 6). Examining CFR and BP at mid-term could have added valuable 
information, but we refrained from anaesthetising the animals twice during pregnancy to 
avoid adverse effects on mother and fetuses. 
A possible explanation for the reduction in CFR at late term in rats could be vasodilatation of 
the coronary vascular bed due to metabolic or endocrine changes in pregnancy. Hirata et al. 
have shown an increase in CFR associated with increasing levels of 17β-estrogen in the 
follicular phase of the menstrual cycle in young, healthy women and after administration of 
conjugated estrogen in postmenopausal women [130]. In third trimester pregnancy estrogen 
levels are high. However, profound changes in several other hormones that occur during 
pregnancy could be responsible for reduced CFR that we observed in rats close to term. 
5.3 Three models of heart hypertrophy in the rat 
Three different models of cardiac hypertrophy were applied to pregnant and non-pregnant rats 
to explore how pregnancy affects cardiovascular adaptation to pathological and physiological 
stress. 
5.3.1 Angiotensin II infusion 
As elaborated in the Introduction RAS is activated in preeclampsia, and the presence of 
autoantibodies to the AngII-receptor type 1 (AT1-AA) may play a key role in the development 
of preeclampsia [50-52]. Thus a model of chronic AngII infusion may be of particular interest 
when exploring the possible mechanism behind heart remodeling in preeclampsia. 
Interestingly, infusion of AngII for 9-10 days led to hypertrophy in terms of a significant 
increased heart weight and LV wall thickness only in pregnant rats (Paper A, Table 3). 
Pregnant AngII infused rats also had increased ejection fraction compared to non-pregnant 
AngII infused rats. Although there were no significant differences in BPs measured in the 
ascending aorta, there was a trend towards lower systolic and diastolic BP in the pregnant 
AngII infused rats compared to non-pregnant AngII infused rats. Thus a difference in BP 
cannot explain increased heart mass. When looking at components related to interstitial 
remodeling such as collagen content, qualitative grading of fibrosis and vessel density, 
pregnant rats were less affected by AngII infusion than non-pregnant rats. As the increase in 
heart mass caused by AngII infusion in pregnancy did not appear to be related to increased 
deposits of extracellular components one would expect an increase in total myocyte mass. 
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However, there was no significant difference in myocyte diameter between any groups. The 
increase in heart mass in pregnant AngII infused rats could be related to an increase in 
myocyte length, which was not measured.  
5.3.2 Transverse aortic constriction 
TAC is used as a model of chronic pressure overload and non-pregnant rats typically develop 
progressive concentric LV hypertrophy and ultimately LV dilatation and heart failure [93] 
(Figure 2). However, in our TAC-study there were no differences in filling pressure, heart 
rate, SV, CO and weight gain between TAC and sham operated animals irrespective of 
whether they were pregnant or not. This indicates that moderate constriction of the transverse 
aorta for ~2 weeks is well compensated with LV hypertrophy and increased stroke work 
(Paper B, Table 1, Figures 2 and 4).  
Women with hypertensive disorders of pregnancy are susceptible to pulmonary edema [131]. 
The more pronounced increase in cardiac stroke work after TAC observed in pregnant rats 
compared to in non-pregnant rats indicate that he hearts of pregnant TAC rats may had 
entered a hypercontractile state with increased myocardial metabolic demand representing the 
stage before decompensated heart failure [132] and thus indicating that pregnancy renders the 
heart more vulnerable to additional stress. A longer time following TAC could lead to overt 
heart failure [93], but the short duration of pregnancy in rats (about 21-22 days) did not allow 
this. Performing TAC before mating, or banding the ascending aorta on juvenile rats [133], 
could be options that may be more relevant to simulate clinical scenarios of pregnancy in 
women with congenital heart defects or acquired heart diseases with LV outflow obstruction, 
and these options should be considered for future studies. However, the effect of aortic 
constriction on fertility in rats is not known. 
5.3.3 High intensity interval training 
We were surprised to find that HIIT for six weeks did not lead to significant heart 
hypertrophy and that HIIT did not significantly change the expression of any of the genes 
related to cardiac hypertrophy we studied.  This lack of cardiac hypertrophy stands in contrast 
to Wisløff et al [94] who reported a significant increase in LV mass of ~10% in female 
Sprague-Dawley rats after four weeks of HIIT and a ~35% increase after 13 weeks. In the 
study by Wisløff et al, the rats exercised for a longer time period (2 h/day) at intervals of 8 
min duration at 85-90% of   O2max[94]. Longer training sessions or longer intervals might 
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have increased the LV mass in animals in the HIIT-study. We felt reluctant to use such an 
aggressive model of HIIT on pregnant rats, and chose a protocol based on what has previously 
been done in mice at our facilities [39] and similar to the more recent studies on rats from 
Wisløffs group [134, 135].  As pregnant rats were able to run ten intervals of four minutes per 
day, and both longer lasting bouts of high intensity running or longer training sessions may be 
tolerated by pregnant rats, and this could be explored in future studies. A longer total period 
of HIIT could have lead to significant increase in LV mass, but due to the short duration of 
pregnancy in rats (~21 days) this was not possible. As the main goal of the study was to 
investigate the effect of HIIT in pregnancy and vice versa we regarded a longer training 
period before mating as not relevant.  
It is a paradox that six week of hard interval training including 24 one hour sessions of HIIT 
with an average total running distance of 83±4 km pr rat did not lead to significant change in 
heart mass or function and that none of the 22 examined genes related to cardiac function and 
remodeling was significantly affected. HIIT rats were able to increase their maximal running 
speed at intervals by 42% during the training period, indicating that their physical fitness was 
improved. Out of animal welfare reasons, HIIT was not performed in the last days of 
gestation, when the rats were heavily pregnant, and thus the rats rested for 2 or 3 days before 
terminal experiments. We chose to do the terminal experiments close to term, at 20 GD, as we 
wanted to investigate the effects of HIIT on the fetus and placenta, and half of the increase in 
fetal and placental weight will take place during the last few days of pregnancy [84]. We 
would not expect cardiac hypertrophy to regress following a couple of days rest towards the 
end of pregnancy. However, the lack of change in expression of genes could be attributed to 
the time lag between cessation of HIIT and collection of samples. The average half-life of 
mRNA (2.6-7 hours) is much shorter than the half-life of proteins (46 hours) in mammalian 
cells [136]. Thus we believe that a long duration from cessation of stimulus (training) to 
sampling of specimens may be the most important explanation for not finding any significant 
changes in expression of mRNAs. In contrast, AngII infusions were continued and the 
increased afterload due to TAC was present until tissues were sampled. 
We used young (9-11 weeks at inclusion) female rats that continued to grow during the 
training period. The hearts of maturing young female rats may respond to the physiologic 
stimuli of pregnancy and/or exercise differently than the heart of mature adult rats. In future 
studies where the primary aim is to investigate effects of HIIT on the heart, one could 
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consider doing terminal experiments and tissue sampling at an earlier stage in pregnancy, 
closer to cessation of HIIT. One could consider using fully grown female rats not needing to 
take into account the natural physical growth of the body and heart in the young, maturing rat. 
Using ultrasound to evaluate cardiac function and to calculate LV mass longitudinally may 
also be possible, but the effects of applying repeated sessions of isoflurane anesthesia in 
pregnancy is not known and repeated procedures could interfere with the intensive training 
regime.   
5.3.4 Comparing models 
Whereas AngII infusion could mimic some of the patho-physiologic changes observed in 
preeclampsia (increased RAS activation), TAC imitates the situation of mechanical 
obstruction of the LV outflow tract as seen in some congenital heart defects (coarctation of 
the aorta, interrupted aortic arch and aortic stenosis). Both interventions lead to an increase in 
afterload, however TAC is in principle a mechanical intervention predominantly leading to an 
increase in systolic BP, whereas by AngII infusion, both diastolic and systolic BP is 
increased. Probably the increased diastolic pressure generated by TAC in the proximal aorta 
is absorbed by increased vascular elastance in the unaffected vascular bed supplied by the 
right brachial artery. AngII leads to increased afterload via its vasoconstricting properties on 
the peripheral circulation. Furthermore there is evidence that AngII stimulate heart 
hypertrophy through direct effects on myocytes as ACE-inhibitors prevents hypertrophy in 
aortic banded rats even if afterload is not reduced [137] , and AngII is able to induces cell 
growth and increases protein synthesis in isolated cardiac myocytes [138].  
The increase in heart weight following AngII infusion was significantly (p=0.006) increased 
in pregnant compared to non-pregnant rats, whereas pregnancy did not significantly affect 
heart weight, LV weight or HW/tibia-ratio following TAC. The increase in mass was not 
related to a higher content of collagen and there was no increase in myocyte diameter. 
Increased myocyte length in pregnancy may account for increased mass; however, there were 
no signs of cardiac dilatation on echocardiography. Water content is increased in heart muscle 
after excessive stretch in dogs [139] and there are reports of increased water content in 
myocytes of pregnant rats [117]. Increased water content may explain an increase in heart 
weight. To our knowledge AngII does not alter water content in cardiac tissue. This could 
easily be addressed in future studies by comparing wet and dry heart weights [117].  
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5.4 Influence of pregnancy on heart remodeling  
Even if pregnancy and HIIT did not lead to significant cardiac hypertrophy, pregnancy per se 
altered expression of a wide range of genes whereas HIIT did not. These data may support 
Chung et al’s assertion that the mechanisms driving the physiologic remodeling following 
exercise are different from those in pregnancy [22, 40] (Table 1). 
5.4.1 Effect of pregnancy on cardiac function in models of increased afterload 
In Paper B we presented pressure-volume data showing that TAC doubled stroke work in 
pregnant rats, whereas the increase in stroke work attributed to TAC in non-pregnant rats was 
only 35% (Paper B, Figure 4D). TAC is used as a model of chronic pressure overload and 
non-pregnant rats generally develop progressive concentric LV hypertrophy and ultimately 
LV dilatation and heart failure [37, 93].  Doenst et al studied the effects of TAC applied in 
juvenile (3 weeks old) Sprague-Dawley rats 2, 6, 10 and 20 weeks later. The pressure 
overload led to progressive heart hypertrophy with preserved systolic cardiac function (EF) at 
2, 6 and 10 weeks and dilatation and impaired function at 20 weeks. However, impairment in 
fatty acid oxidation and reduced cardiac power was demonstrated ex vivo as early as 2 weeks 
after TAC [37]. In the TAC-study there were no differences in filling pressure, heart rate, EF, 
CO and weight gain between TAC and sham operated animals irrespective of whether they 
were pregnant or not, indicating that a moderate constriction of the transverse aorta for ~2 
weeks is well compensated with LV hypertrophy and increased stroke work. As expected 
TAC increased afterload, but the increase in afterload attributed to TAC was not affected by 
pregnancy. In contrast to chronic pressure load caused by AngII, aortic diastolic BP was not 
affected by TAC. The increase in systolic afterload caused by TAC was compensated by an 
increase in stroke work and this increase was more pronounced in pregnant animals. This may 
be related to the fact that pregnancy in combination with TAC led to an increase in myocyte 
circumference. Additionally, cardiac remodeling following TAC was associated with a more 
than three-fold increase in the ratio of β-MHC/α-MHC-gene expression in pregnant compared 
to non-pregnant rats. 
5.4.2 Influence of pregnancy on cardiomyocytes 
As discussed earlier (5.2.1) pregnancy per se did not lead to significant increase in myocyte 
diameter or circumference, and heart hypertrophy following AngII for ~10 days or TAC for 
~2 weeks did not increase the myocyte diameter/circumference significantly. However, the 
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myocyte transverse circumference was significantly higher in pregnant TAC rats compared to 
non-pregnant sham operated rats. An increased β-MHC expression and decrease in α-MHC 
expression has been considered as hallmarks of cardiac hypertrophy [140, 141]. As expected, 
expression of β-MHC was increased and expression of α-MHC was decreased following 
TAC. Interestingly this shift in MHC-expression towards the β- isoform was more 
pronounced in pregnant rats. A recent study in mice has shown that β-MHC protein is induced 
by pressure overload only in a minor subpopulation of myocytes that  are smaller than 
myocytes containing α-MHC only [142]. This may explain why TAC for ~2 weeks did not 
lead to an increase in average myocyte circumference even if the ratio of β-MHC to α-MHC 
expression and contractility was increased.  
5.4.3 Myocardial fibrosis in pregnancy 
In Paper A we showed that AngII infusion for ~10 days lead to a marked deposition of 
extracellular collagen and that pregnancy opposed this effect. There was a significant increase 
in the expression of COL3A1 in AngII and a trend towards less expression of fibrosis related 
genes COL1A1, COL3A1 and FN1 in AngII treated pregnant rats compared to AngII treated 
non-pregnant rats (Paper A, Figure 1 and Table 5). In Paper B the up-regulation of COL1A1, 
COL3A1, FN1 and TIMP1 genes was less pronounced following TAC for ~14 days compared 
to following AngII infusion and there was no increase in collagen deposition. Pregnancy 
increased the expression of TIMP1 independent of TAC (p=0.02). There was a non-
significant trend towards less expression of COL1A1 and COL3A1 in pregnant compared to 
non-pregnant TAC (Paper B, Figure 3B and Tables 2 and 3). In Paper C, the expression of 
COL1A1, COL3A1 and TIMP1 genes was reduced by pregnancy, but not affected by HIIT. 
As HIIT did not lead to significant change in cardiac mass or changes in gene expression and 
fibrosis is not induced by exercise training, we did not analyze collagen content in tissue in 
the HIIT study.  
The difference in myocardial response to increased afterload caused by AngII compared to the 
effects of obstruction of LV outflow tract is probably related to the direct effect AngII on the 
heart independent of increase in BP [137, 138, 143]. TGF-β acts as a regulator of cardiac 
remodeling through its direct actions on the cardiomyocyte, the fibroblast and the 
extracellular matrix, and is induced by hemodynamic overload [144]. TGF-β1 acts 
downstream to AngII in inducing myocardial fibrosis [144]. The expression TGF-β genes was 
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not examined in Paper A, but in Papers B and C the expression of TGF-β1, TGF-β2 and TGF-
β3 in LV myocardium was lower in pregnant compared to non-pregnant rats, both in 
intervention groups and in controls. Thus downregulation of TGF-β signaling pathways may 
explain why pregnancy counteracts the development of fibrotic remodeling of the LV in 
AngII infused rats presented in Paper A. In addition, some AngII-receptors are less sensitive 
to AngII during pregnancy as they are switched from a heterodimeric to a monomeric state 
that is inactivated by reactive oxygen species [28]. Furthermore, the high estrogen levels of 
late pregnancy may inhibit fibrosis via direct effects on the estrogen receptor-β in cardiac 
fibroblast and cardiomyocytes [145]. 
Heart hypertrophy following TAC for ~14 days did not lead to significant myocardial fibrosis, 
but fibrosis is inevitable if the heart is exposed to increased afterload for a longer period of 
time [93]. However, due to the short gestation (~21 days), rat models with banding of the 
aorta may not be suitable to determine if pregnancy  protects against fibrosis following 
increased LV outflow obstruction as seen in pregnant women with congenital heart defects.  
5.4.4 Effects of pregnancy on the coronary circulation in models of increased 
afterload 
Effects of pregnancy and increased afterload on the coronary circulation were evaluated in 
several ways; through measurement of expression of genes related to angiogenesis, by 
evaluating vessel density and by using CFR measurements to evaluate endothelial function.  
5.4.4.1 Microcirculation and vessel density 
Gene expression of VEGF-α and VEGF-β was decreased in pregnant compared to non-
pregnant rats in all studies (Paper A; Table 5, Paper B; Tables 2 and 3, Paper C; Table 2).  
None of the examined interventions (AngII, TAC or HIIT) influenced the expression of 
VEGF-α or VEGF-β. In the AngII-study, vessel density tended to increase in pregnant 
compared to non-pregnant in both sham and AngII infused rats, and decrease in both pregnant 
and non-pregnant AngII infused rats (Paper A, Figure 2). Thus we concluded that pregnancy 
may counteract the detrimental effects of AngII on angiogenesis in the heart. VEGF-α is an 
angiogenic factor activated by hypoxia and is essential for angiogenesis and remodeling in 
several organs, including the heart [146]. Expression of VEGF-β is critical for the survivel of 
vascular endothelial cells [147]. Unlike in other studies [101], AngII alone did not increase 
the expression of VEGF in this study, and the decrease in vessel density in AngII infused rats 
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was not accompanied with significant changes in  VEGF expression.  Furthermore, the 
increase in vessel density in pregnancy was accompanied with lower expression of VEGF. 
Thus vessel density in the heart in AngII treated rats might be regulated through other 
mechanisms than the VEGFs or the change in of VEGF gene expression is not reflected at the 
protein level. 
5.4.4.2 Coronary flow reserve 
In contrast to previous findings in dogs [148] and mice [149] with increased afterload , in our 
study CFR was not reduced by AngII infusion or TAC in rats. In addition to species 
differences, there could be several other reasons for this discrepancy. Hittinger et al. found 
that CFR was preserved in dogs with compensated heart hypertrophy, but was exhausted 
when the dogs developed decompensated pressure overload left ventricular hypertrophy 
[148].  In our studies the animals did not have decompensated heart failure when CFR was 
measured .   
The course and outcome of pregnancy may be affected by maternal heart disease [150], and 
death from heart disease is the leading cause of indirect maternal death in the UK [151]. A 
recent study showed that the utero-placental blood flow is impaired in pregnant women with 
congenital heart diseases [152]. As the effects of pregnancy on CFR have not been studied 
before, and it is not known if reduced CFR can predict an increased risk of adverse 
cardiovascular events in pregnancy, there is a need for non-invasive tests to asses risk and 
predict outcome in pregnant women at risk.  Thus, studies of CFR in healthy human 
pregnancies and in pregnant women with hypertension or heart diseases using non-invasive 
methods and a safe vasodilating agent are warranted. Adenosine is probably safe, but is 
associated with unpleasant side effects such as dyspnea, chest discomfort and transient 
asystole. Dipyridamole, a FDA category B drug, could be a safe alternative [127]. 
Inhalation of isoflurane is not an alternative for pregnant women, but the findings in Paper D 
indicates that estimating CFR using different concentrations of isoflurane is an easy, quick 
and non-invasive method of evaluating CFR in research animals. This is of particular 
importance when several procedures are scheduled as increased time in anesthesia increases 
the risk of destabilizing the animal and thus failure in getting valuable results from the study.  
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5.5 High intensity interval training during pregnancy 
HIIT was well tolerated by pregnant rats. However, six weeks of HIIT did not lead to 
significant changes in cardiac structure, function, and gene expression irrespective of whether 
the rats became pregnant or not. As high-intensity training in humans leads to heart 
hypertrophy, and others have demonstrated hypertrophy in rats subjected to HIIT [94], one 
could argue that the rats were not exposed to adequate doses of training. However, as the rats 
ran ten bouts of four minutes at 85-90% at    2max five days/week for six weeks, this is not 
likely. Looking at the translational aspect of our experiments it is not likely that even the most 
vigorously training pregnant women would train at this level during pregnancy.  
HIIT did not affect body weight significantly in non-pregnant or pregnant rats and all rats 
gained weight during the course of experiments. This suggests that HIIT is not effective in 
reducing weight in young female non-obese rats, independent of pregnancy status. Maternal 
obesity and excessive weight gain in pregnancy are known risk factors for adverse pregnancy 
outcomes [66, 153]. As the prevalence of obesity in pregnancy is increasing [66], from a 
translational perspective it would be of interest to examine the effects of HIIT in pregnant 
obese animals. It is possible that the ratio of skeletal muscle to adipose tissue mass is affected 
by training. Measures of body composition and other markers of metabolic profile could be 
addressed in future studies on HIIT in pregnancy. 
The present study was performed in young, healthy rats. In the developed world the average 
maternal age is rising [154] and in future studies one could consider replacing young, 
adolescent rats with fully mature rats to add translational relevance.  
5.6 Rat models of heart hypertrophy and the fetus 
None of the interventions tested, i.e. HIIT carried out from 3 weeks before pregnancy and 
continued until 2-3 days before term gestation, chronic AngII infusion or TAC in the last half 
of pregnancy, led to significant changes in fetal or placental size or the litter size. In the 
AngII-study the fetal hemodynamics was not affected (Appendix 2). There were subtle 
changes in gene expression in fetal heart in all three studies, but no consistent differences in 
findings were observed (Paper C, Table 5 and Appendix 3 and 4). Based on our findings, we 




One of the objectives of our study was to evaluate the safety of HIIT in pregnancy. In HIIT 
fetuses there were some minor changes in gene expression in liver tissue indicative of 
oxidative stress, but we did not find any significant changes in ROS-activity in placenta, fetal 
liver or heart (Paper C, Figures 3 and 4). A more extreme model of HIIT (longer training 
sessions, longer intervals, HIIT continued until term) might compromise fetal wellbeing, but 
the translational relevance of such protocol is questionable and there would be obvious animal 
welfare concerns. The changes in gene expressions were small and the translational 
significance of these findings is uncertain. However, they may indicate that protective 
mechanisms are activated. Thus, before extensive training at the anaerobic threshold can be 
ruled in as safe in pregnancy, our findings should be tested by other researchers and 
preferably in other animal species. Based on the combined experience, clinical studies with 




6. Main conclusions 
 Cardiac remodeling caused by chronic infusion of moderate doses of AngII in 
pregnant rats is associated with heart hypertrophy. However, pregnancy protected 
against fibrosis and preserved angiogenesis in AngII infused rats.  
 Some differences in cardiac structure, function and gene expression observed between 
pregnant and non-pregnant rats following TAC indicate that afterload increase is less 
tolerated in pregnancy.  
 Pregnancy induces changes in the expression of a wide range of genes involved in 
cardiac remodeling independent of afterload. 
 Pregnancy per se does not lead to heart hypertrophy in rats. Therefore, rat models may 
not be suitable for studying physiological heart hypertrophy of pregnancy. 
 It is feasible to measure CFR in rats non-invasively using Doppler echocardiography 
and high concentration of inhaled isoflurane as the vasodilating agent. 
 CFR is reduced in late pregnancy in rats. CFR is not affected by increased LV 
afterload caused by chronic infusion of moderate doses of Ang II or TAC, regardless 
of pregnancy status. 
 HIIT is feasible and well tolerated by pregnant rats. It does not appear to alter 
maternal cardiac structure or function, and oxidative stress and total antioxidant 
capacity in the placenta, fetal heart and fetal liver. 
 Litter size, placental weight and fetal size are not affected by AngII infusion, TAC or 
HIIT. Some genes related to cardiac function and oxidative stress are altered in the 




7. Translational relevance and future perspectives 
Management of pregnant women with cardiac disease or hypertension remains a challenge. 
Experimental studies on cardiac remodeling in pregnancy, especially those relevant to heart 
diseases and pregnancy complications are sparse. Studies presented in this thesis try to 
explore basic mechanisms involved in cardiovascular adaptation to pregnancy under 
physiological and pathological circumstances, and therefore have some translational value. 
However, further studies are needed to better understand physiological and pathological 
cardiac remodeling in pregnancy at basic and clinical levels that may lead to new therapeutic 






Paper C, page 20. 
Table 2 Maternal myocardial expression of genes related to cardiac remodeling in pregnant 
and non-pregnant HIIT compared to pregnant and non-pregnant sedentary rats and influence 
of pregnancy on gene expression 
Influence of pregnancy (sixth column); ns (not significant) , corrected to na (non-applicable) 
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Echocardiography performed on pregnant and non-pregnant rats infused with saline or 
angiontensin II 
 Sham Pregnant  AngII  Pregnant 
AngII 
M-mode echocardiography (n) 7 14 8 14 
Fraction of shortening (%) 44±4 46±2 54±5 61±4
*#
 
Ejection fraction (%) 72±4 76±2 82±5 88±3
*#
 
Stroke volume (µL) 149±13 158±10 141±10 132±11 
Cardiac output (mL/min) 59±4 68±4 61±4 55±5 
LV inner diameter in diastole 
(mm) 
1.6±0.1 1.6±0.1 1.8±0.1 2.0±0.1 
LV relative wall thickness (%) 51±4 45±3 57±2 76±7
*#
 
LV mass (g) 0.64±0.02 0.58±0.04 0.61±0.04 0.72±0.06 
Doppler echocardiography (n) 6 15 8 14 
Mitral valve E/A-ratio 0.99±0.04 1.13±0.03 1.04±0.04 1.01±0.04 
Isovolumetric contraction time 
(ms) 
15±1 15±1 13±1 14±1 
Isovolumetric relaxation time (ms) 18±2 19±2 20±3 21±2 
Tei-index 0.59±0.05 0.64±0.05 0.63±0.09 0.70±0.06 
Data were analyzed using one-way ANOVA and Holm-Sidak post hoc test and is presented as 






Fetal echocardiography performed on pregnant rats infused with saline (sham) and 
angiotensin II  




























































Protein kinase C α 1.00±0.05 0.99±0.05 0.9 
Protein kinase C δ  1.00±0.03 1.00±0.05 1.0 
Protein kinase C ε 1.00±0.05 1.03±0.02 0.6 
α-Myosin heavy chain 1.00±0.09 0.97±0.14 0.8 
β-Myosin heavy chain 1.00±0.07 1.03±0.05 0.8 
Atrial natriuretic peptide 1.00±0.05 1.06±0.11 0.6 
Brain natriuretic peptide 1.00±0.08 1.31±0.11 0.031 
Vascular endothelial growth factor-α 1.00±0.07 1.03±0.06 0.7 
Vascular endothelial growth factor-β 1.00±0.05 1.00±0.05 1.0 
Superoxide dismutase 1 1.00±0.04 0.99±0.05 0.9 
Superoxide dismutase 2 1.00±0.04 1.01±0.01 0.9 
Inducible nitric oxide synthase 1.00±0.04 0.84±0.06 0.025 
Tissue inhibitor of metallopeptidase 1 1.00±0.11 0.89±0.10 0.5 
Tissue inhibitor of metallopeptidase 3 1.00±0.04 1.11±0.05 0.08 
Tissue inhibitor of metallopeptidase 4 1.00±0.06 0.90±0.05 0.3 
Hypoxia-inducible factor 1α 1.00±0.3 0.99±0.04 0.8 
Relative expression of genes in fetal heart tissue normalized to mean values in fetuses of sham 





Gene expression of fetal hearts of rats subjected to transverse aorta constriction 








Protein kinase C α 1.00±0.07 1.10±0.10 0.4 
Protein kinase C δ  1.01±0.02 1.06±0.02 0.1 
Protein kinase C ε 1.03±0.06 1.10±0.11 0.6 
α-Myosin heavy chain 0.98±0.08 1.12±0.15 0.4 
β-Myosin heavy chain 0.99±0.13 1.05±0.09 0.8 
Atrial natriuretic peptide 1.14±0.14 1.02±0.29 0.7 
Brain natriuretic peptide 0.92±0.07 0.96±0.11 0.7 
Vascular endothelial growth factor-α 0.98±.011 1.01±0.12 0.9 
Vascular endothelial growth factor-β 1.02±0.02 1.20±0.09 0.06 
Superoxide dismutase 1 0.96±0.08 0.92±0.07 0.8 
Superoxide dismutase 2 0.99±0.07 0.86±0.09 0.3 
Inducible nitric oxide synthase 0.92±0.08 1.20±0.09 0.6 
Tissue inhibitor of metallopeptidase 1 0.93±0.12 0.97±0.18 0.9 
Tissue inhibitor of metallopeptidase 3 0.97±0.09 0.89±0.09 0.6 
Tissue inhibitor of metallopeptidase 4 1.03±0.10 1.20±0.20 0.4 
Hypoxia-inducible factor 1α 0.90±0.08 0.87±0.10 0.8 
Relative expression of genes in fetal heart tissue normalized to mean values in female fetuses 
of sedentary rats. Data is presented as mean of the mean value of fetuses in each pregnant rat 









GADPH: Glyceraldehyde-3phosphate dehydrogenase 
CTG-CAC-CAC-CAA-CTG-CTT-AC 
CAG-AGG-TGC-CAT-CCA-GAG-TT 






B2M: β-2 microglobulin 
TGC-CAT-TCA-GAA-AAC-TCC-CC 
GAG-GAA-GTT-GGG-CTT-CCC-ATT 
LDHA: Lactate dehydrogenase 
GAT-CTC-GCG-CAC-GCT-ACT 
CAC-AAT-CAG-CTG-GTC-CTT-GAG 
SDHA: Succinate dehydrogenase complex, subunit A 
CCC-TGA-GCA-TTG-CAG-AAT-C 
CAT-TTG-CCT-TAA-TCG-GAG-GA 







PKC-α: Protein kinase C-α 
CAA-GCA-GTG-CGT-GAT-CAA-TGT 
GGT-GAC-GTG-CAG-CTT-TTC-ATC 
PKC-δ: Protein kinase C-δ 
TCA-AGA-ACC-ACG-AGT-TCA-TCG 
GCA-TTG-CCT-GCA-TTT-GTA-GC 
PKC-ε: Protein kinase C-ε 
CGT-CAC-TGA-TGT-GTG-CAA-TG 
TCG-AAC-TGG-ATG-GTG-CAG-TTG 
α-MHC: α-Myosin heavy chain 
CAA-GGC-AAA-CCT-GGA-GAA-AG 
GGG-TAT-AGG-AGA-GCT-TGC-CC 
β-MHC: β- Myosin heavy chain 
GAG-GAG-AGG-GCG-GAC-ATT 
ACT-CTT-CAT-TCA-GGC-CCT-TG 
ANP: Atrial natriuretic peptide 
CAA-CAC-AGA-TCT-GAT-GGA-TTT-CA 
CGC-TTC-ATC-GGT-CTG-CTC 






Studied genes cont.: 
ANKRD1: Ankyrin repeat domain-containing protein 1 
GCTGGAGCCCAGATTGAA 
CTCCACGACATGCCCAGT 
TNF-α: Tumor necrosis factor-α 
GCC-CAG-ACC-CTC-ACA-CTC 
CCA-CTC-CAG-CTG-CTC-CTC-T 
TGF-β1: Transforming growth factor β1  
AAG-AAG-TCA-CCC-GCG-TGC-TA 
TGT-GTG-ATG-TCT-TTG-GTT-TTG-TCA 
TGF-β2: Transforming growth factor β2 
ATC-GAT-GGC-ACC-TCC-ACA-TAT-G 
GCG-AAG-GCA-GCA-ATT-ATC-CTG 






VEGF-α: Vascular endothelial growth factor-α 
CAA-GCC-AAG-GCG-GTG-AGC-CA 
TCT-GCC-GGA-GTC-TCG-CCC-TC 
VEGF-β: Vascular endothelial growth factor-β 
ACC-AGA-AGA-AAG-TGG-TGT-CAT-G 
TGA-GGA-TCT-GCA-TTC-GGA-CTT-G 





SOD1: Superoxide dismutase 1 
TTC-GTT-TCC-TGC-GGC-GGC-TT 
TTC-AGC-ACG-CAC-ACG-GCC-TT 
SOD2: Superoxide dismutase 2 
ATT-AAC-GCG-CAG-ATC-ATG-CA 
CCT-CGG-TGA-CGT-TCA-GAT-TGT 
eNOS: Endothelial nitric oxide synthase  
TGA-CCC-TCA-CCG-ATA-CAA-CA 
CGG-GTG-TCT-AGA-TCC-ATG-C 
iNOS: Inducible nitric oxide synthase 
ACCATGGAGCATCCCAAGTA 
CAGCGCATACCACTTCAGC 
TP53: Tumour suppressor gene(TP53) 
GTT-AGG-GGG-TAC-CTG-GCA-TC 
CGA-CTG-TGA-ATC-CTC-CAT-GA 
Casp-3: Apoptosis related cysteine protease; caspase 3 
CCG-ACT-TCC-TGT-ATG-CTT-ACT-CTA 
CAT-GAC-CCG-TCC-CTT-GAA 
Bcl-2: B-cell leukaemia/lymphoma 2 
GTA-CCT-GAA-CCG-GCA-TCT-G 
GGG-GCC-ATA-TAG-TTC-CAC-AA 
COL1A1: Collagen type I-α1 
CAT-GTT-CAG-CTT-TGT-GGA-CCT 
GCA-GCT-GAC-TTC-AGG-GAT-GT 
COL3A1: Collagen type III-α1 
TCC-CCT-GGA-ATC-TGT-GAA-TC 
TGA-GTC-GAA-TTG-GGG-AGA-AT 




TIMP1: Tissue inhibitor of metallopeptidase 1 
CAG-CAA-AAG-GCC-TTC-GTA-AA 
TGG-CTG-AAC-AGG-GAA-ACA-CT 
TIMP 3: Tissue inhibitor of metallopeptidase 3 
GAA-CGG-AAG-CGT-GCA-CAT-G 
CAG-CTT-CTT-TCC-CAC-CAC-TTT-G 
TIMP 4: Tissue inhibitor of metallopeptidase 4 
AGG-GAG-AGC-CTG-AAT-CAT-CA 
GCA-CTG-CAT-AGC-AAG-TGG-TG 


























GPx1: Glutathione peroxidase 1 
AGT-TCG-GAC-ATC-AGG-AGA-A 
AGG-GCT-TCT-ATA-TCG-GGT-TC 
GPx2: Glutathione peroxidase 2 
GCC-TAG-TGG-TTC-TCG-GCT-TCC 
AGG-GTA-GGG-CAG-CTT-GTC-TTT-C 
GPx4.1: Glutathione peroxidase 4 transcript variant 1 
GCC-GCT-TAT-TGA-AGC-CAG-C 
GTG-GGC-ATC-GTC-CCC-ATT-TA 
GPx4.2: Glutathione peroxidase 4 transcript variant 2 
CCC-ATT-CCC-GAG-CCT-TTC-AA 
TAT-CGG-GCA-TGC-AGA-TCG-AC 
Ddx3y: DEAD box polypeptide 3, Y-linked 
ACG-GTG-GCT-TGC-TCC-GTG-AA 
GCC-AAC-CGT-ATT-TTC-CGC-CGC 
Eif2s3y: eukaryotic translation initiation factor 2, 
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